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Abstract 
Age-related macular degeneration (AMD) is one of the leading causes of blindness in the 
United States in people who are 50 and older.  The safety and efficacy of aflibercept for 
the treatment of late stage neovascular AMD (NAMD) has been demonstrated by clinical 
trials among several populations; however, it is unclear whether all NAMD patients 
respond in the same manner as was studied in the clinical trials.  The purpose of this 
study was to examine if populations of patients treated with aflibercept for the treatment 
of NAMD were significantly different from one another in terms of health characteristics, 
treatment regimens, and treatment outcomes. The burden of treatment theory was used to 
guide this study.  Data collected from electronic medical records were used to investigate 
NAMD characteristics 199 patients from 3 private, retinal practices in the United States.  
Data were analyzed using one-way ANOVA, c2, Spearman’s correlation, and point-
biserial correlation tests.  The results of this study showed the specific retinal practice 
populations of NAMD patients treated with aflibercept were generally similar with 
respect to selected health characteristics, treatment regimens, and treatment outcomes.  
By using the information reported from this research, public health initiatives can be 
developed that focus on the need for early detection of AMD to capture changes that 
represent NAMD and move to early treatment for better outcomes.  The positive social 
change that could result from this research is that retinal specialists may gain insight into 
the use and outcomes of aflibercept treatment. 
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Chapter 1: Introduction to the Study 
Introduction 
Age-related macular degeneration (AMD) is the leading causes of blindness in the 
United States in people 50 years of age and older (National Eye Institute [NEI], 2014).  
Further, the NEI (2014) reported the U.S. 2010 prevalence of AMD for all ages and all 
races/ethnicities to be 2.09% translating to 2,069,403 cases.  Projections for increase in 
AMD are estimated to be 3,664,044 by 2030 and 5,442,265 by 2050 (NEI, 2014).  The 
majority of patients with AMD of all types are Caucasian (prevalence 2.46%) and 86% of 
patients with AMD are female (NEI, 2014).  The risk of developing AMD increases 
significantly with aging from 0.36% in the 50s to 11.73% in the 80s (NEI, 2014).   
The burden of AMD encompasses not only vision loss, but also issues of 
depression, falls, and cost in time and finances for treatment (Dawson, Mallen, 
Gouldstone, Yarham, & Mansell, 2014; Silver, 2014; Wood et al., 2011).  Treatment for 
neovascular AMD (NAMD) with current vascular endothelial growth factor inhibitors 
(anti-VEGF) was estimated to be approximately 1 to 2 billion dollars per year, which is 
approximately 10% of the total Medicare Part B drug apportionment budget per year 
(Silver, 2014).  One objective of the U.S. health improvement and disease prevention 
program, Healthy People 2020, is to reduce the incidence of AMD by 10% from 15.5 per 
1,000 individuals to 14.0 per 1,000 (Department of Health and Human Services [DHHS], 
2015).  More specifically, the goal is to reduce the impact of visual impairment and 
disability caused by AMD in the population in which AMD is most prevalent (i.e., 
individuals 45 years of age and older; DHHS, 2015).  In support of this objective, 
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researchers in ophthalmology investigate disease mechanisms and risk factors in order to 
design and develop novel therapeutic interventions in this disease population (Avery et 
al., 2014; Hagstrom et al., 2013; Kovach, Schwartz, Flynn, & Scott, 2012).  
Before being marketed, therapeutic interventions must undergo strict clinical 
research testing according to the U.S. Food, Drug, and Cosmetic Act (Federal Food, 
Drug, and Cosmetic Act, 1938).  While clinical trials are performed to establish the safety 
and efficacy of new therapies, research at this level can only begin to describe how a 
therapeutic agent may perform in all populations in which the disease manifests (Drolet 
& Lorenzi, 2011).  Consequently, researchers must continue to evaluate interventions in 
targeted populations to provide ongoing information pertinent to the use of new therapies.  
Elucidating information, such as ongoing evaluation of therapeutic agents, could lead to 
positive social change by ensuring developers of new drug products take into 
consideration how differences in population characteristics could impact clinical 
outcomes.   
In Chapter 1, I will examine the background of AMD and provide information 
pertaining to how this study extended the knowledge base regarding use of aflibercept in 
NAMD by evaluating selected health characteristics, treatment regimens, and treatment 
outcomes of a novel therapeutic intervention in populations of NAMD patients.  In 
Chapter 1, I will also elaborate the nature of the study performed, including the research 
questions and hypotheses addressed in the study.  In the remainder of Chapter 1, I will 
address the assumptions, limitations, and significance of this research, and I will preview 
the remaining chapters. 
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Background of the Study 
AMD is a progressive and chronic ophthalmic condition wherein changes to the 
macula of the eye manifest and have an impact on visual function (Lim, Mitchell, 
Seddon, Holz, & Wong, 2012).  The various phases of AMD are characterized by 
increasingly severe anatomical manifestations ranging from (a) early AMD wherein fatty 
deposits (i.e., drusen) form that create little visual disturbance (NEI, 2015b); (b) 
intermediate AMD, in which drusen become larger and changes in the color and 
appearance of the retinal pigment epithelium (RPE) become evident (NEI, 2015b); and 
(c) the late phase, in which either increased atrophy in the RPE, choriocapillaris, and 
photoreceptors, known as geographic atrophy (GA), or the development of new blood 
vessels into the choroidal space of the macula, known as choroidal neovascularization 
(CNV), manifests (Lim et al., 2012).  Risk factors noted to be associated with AMD, 
include increased age, cigarette smoking, cataract extraction, and family history of AMD 
(Chakravarthy et al., 2010).  Lim et al. (2012) further noted hyperopic refraction and 
sunlight exposure as significant risk factors. 
The early and intermediate forms of AMD have little impact on visual function; 
therefore, prophylaxis rather than treatment is the focus of these phases (Singer, Amir, 
Herro, Porbandarwalla, & Pollard, 2012).  Once a patient’s disease has progressed to 
NAMD, the standard of care treatment is injections with anti-VEGF drugs (e.g., 
ranibizumab, bevacizumab, or aflibercept) that are designed to inhibit proliferation of 
new blood vessels (Gower, 2012; Rakic et al., 2013).  In general, anti-VEGF injections 
are intended to be given on a monthly basis for at least 3 months after which the schedule 
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of additional injections is based on visual function results achieved (Kovach et al., 2012; 
Rakic et al., 2013).  Obviously, treatment outcomes vary; however, investigators have 
reported that patients may regain as much as 50% of the vision lost in the initial 
onslaught of NAMD, if the condition is caught early (Lim et al., 2012).  The three anti-
VEGF drugs currently approved for treatment of NAMD (i.e., Avastin, Macugen, and 
Eylea) are quite costly and make up a substantial portion of Medicare Part B payouts 
(Levinson, 2011).  A fourth drug, bevacizumab, is often used “off label” to treat NAMD 
as it is significantly cheaper than the alternatives; however, the practice of “off label” 
treatment with bevacizumab has not been supported by the Office of Inspector General as 
its safety and efficacy have not been evaluated in the NAMD population (Levinson, 
2011).   
Through the process of deduction, I determined an appropriate approach for this 
study to be to evaluate the gap in the discipline that existed regarding specifically 
identified populations to determine whether selected health characteristics, treatment 
regimens, and treatment outcomes were significantly different between population 
centers.  Furthermore, I determined the need to evaluate what associations existed 
between selected health characteristics, treatment regimens, and treatment outcomes in 
the selected population centers.  The results of a study exploring the identified gap should 
lead to a better understanding of not only which patients should be treated and what the 
best treatment regimen was for the optimal outcome but also what impact treatment had 
on personal and public heath burden. 
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Problem Statement 
While the safety and efficacy of aflibercept for the treatment of NAMD was 
demonstrated in clinical trial populations to the satisfaction of the Food and Drug 
Administration (FDA; Heier et al., 2012), the issue of ongoing evaluation of this 
treatment continues.  As with prior anti-VEGF treatments, the matter was unclear 
whether all populations of NAMD respond in the same manner as was studied in the 
clinical trials used to support the marketing of aflibercept (Al-Qureshi & Shaikh, 2012; 
Chakravarthy et al., 2012; Rakic et al., 2013).  NAMD treatment costs make up a 
substantial portion of the payouts made by Medicare; therefore, appropriate treatment of 
patients who will gain the most benefit is of utmost importance to both the personal and 
public financial burden created by NAMD (Schmier, Covert, & Lau, 2012; Silver, 2014; 
Stein, Hanrahan, Comer, & Sloan, 2013).   
By evaluating selected health characteristics, aflibercept treatment regimens, and 
aflibercept treatment outcomes of NAMD patients in geographically disperse population 
centers, I aimed to add to the body of knowledge pertaining to how aflibercept was being 
used, should be used, and in what patient populations aflibercept was the most 
appropriate treatment.  My goal was to address whether significant differences existed 
regarding selected health characteristics, treatment regimens, and treatment outcomes for 
patients with NAMD treated with aflibercept from three private, retinal practices in 
geographically disperse population centers in the United States.  Potential associations 
between selected health characteristics, treatment regimens, and treatment outcomes were 
evaluated to address the gap in the literature related to aflibercept and how aflibercept 
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treatment for NAMD performs in populations with characteristics different from or 
treated in a manner that differed from the clinical trial populations.   
Purpose of the Study 
The primary purpose of this quantitative, secondary data analysis was to 
determine if differences exist between geographically disperse NAMD patient 
populations treated with aflibercept (grouping variable) with regard to selected health 
characteristics (independent variables).  The secondary purpose was to evaluate 
associations that may be present between populations.  This evaluation would aid in 
determining if and how selected health characteristics (independent variables) and 
aflibercept treatment regimens (independent variables) impacted treatment outcomes 
(dependent variables).    
Research Questions and Hypotheses 
I conducted evaluations using patients from three private, retinal practices in 
geographically disperse populations centers in the United States who had been diagnosed 
with NAMD and had been treated with aflibercept.  The following research questions 
were addressed: 
Research Question 1: Were there significant differences between selected health 
characteristics of populations of NAMD patients treated with aflibercept in three 
private, retinal practices in geographically disperse population centers in the 
United States? Health characteristic variables included: age, gender, number of 
ocular comorbidities, number of systemic comorbidities, number of days between 
NAMD diagnosis and first treatment with aflibercept in the study eye, baseline 
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best corrected visual acuity (BCVA), and baseline optical coherence tomography 
(OCT). 
H01: µ1=µ2 
There were no differences in proportions between selected health 
characteristics of populations of NAMD patients treated with aflibercept 
in three private, retinal practices in geographically disperse population 
centers in the United States. 
Ha1: µ1≠µ2 
There were differences in proportions between selected health 
characteristics of populations of NAMD patients treated with aflibercept 
in three private, retinal practices in geographically disperse population 
centers in the United States. 
Research Question 2: Were there significant differences between aflibercept 
treatment regimens used to treat NAMD patient in three private, retinal practices 
in geographically disperse population centers in the United States? Treatment 
regimen variables included: average number of aflibercept treatments injections 
received during 1 year from initial aflibercept treatment and average number of 
days between aflibercept treatments. 
H02: µ1=µ2 
There were no differences in the aflibercept treatment regimens used to 
treat populations of NAMD among patients at three private, retinal 
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practices in geographically disperse population centers in the United 
States. 
Ha2: µ1≠µ2 
There were differences in aflibercept treatment regimens used to treat 
populations of NAMD among patients at three private, retinal practices in 
geographically disperse population centers in the United States. 
Research Question 3: Were there significant differences between aflibercept 
treatment outcomes reported for NAMD patients in the three private, retinal 
practices in geographically disperse population centers in the United States? 
Treatment outcome variables included: average change from baseline in BCVA 
and average change from baseline in OCT. 
H03: µ1=µ2 
There were no differences between aflibercept treatment outcomes 
reported for NAMD patients in three private, retinal practices in 
geographically disperse population centers in the United States. 
Ha3: µ1≠µ2 
There were differences between aflibercept treatment outcomes reported 
for NAMD patients in three private, retinal practices in geographically 
disperse population centers in the United States. 
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Research Question 4: What associations existed between selected health 
characteristics and aflibercept treatment regimens used to treat NAMD patients in 
three private, retinal practices in geographically disperse population centers in the 
United States? 
H04: ßĸ=0 
There were no associations between selected health characteristics and 
aflibercept treatment regimens used to treat NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
Ha4: ßĸ≠0 
There were associations between selected health characteristics and 
aflibercept treatment regimens used to treat NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
Research Question 5: What associations existed between selected health 
characteristics and aflibercept treatment outcomes reported for NAMD patients in 
three private, retinal practices in geographically disperse population centers in the 
United States? 
H05: ßĸ=0 
There were no associations between selected health characteristics and 
aflibercept treatment outcomes reported for NAMD patients in three 
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private, retinal practices in geographically disperse population centers in 
the United States. 
Ha5: ßĸ≠0 
There were associations between selected health characteristics and 
aflibercept treatment outcomes reported for NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
Research Question 6: What association existed between aflibercept treatment 
regimens used and aflibercept treatment outcomes reported for NAMD patients in 
three private, retinal practices in geographically disperse population centers in the 
United States? 
H06: ßĸ=0 
There were no associations between aflibercept treatment regimens used 
and aflibercept treatment outcomes reported for NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
Ha6: ßĸ≠0 
There were associations between aflibercept treatment regimens used and 
aflibercept treatment outcomes reported for NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
11 
 
Theoretical Framework 
May, Montori, and Mair (2009) described the theoretical framework of burden of 
treatment as based on recognition that chronic disease was increasingly burdensome for 
patients, not just because of the health issues related to the disease, but also due to the 
treatments prescribed for chronic diseases.  May et al. discussed the impact complicated 
treatments may have on patients due to nonadherence as causing additional health 
complications along with financial and health burdens associated with changes in health 
status.  These researchers called for minimally disruptive treatments and treatment 
regimens that could be managed by patients with chronic conditions.  May et al. (2014) 
further elaborated on the burden of treatment theory as being the predominant manner by 
which to describe a patient’s “struggles to endure the symptoms of illness and to look 
after themselves and others” (p. 1).   
As the life span of humans has increased, the face of illness has changed from 
acute, infectious disease to chronic, long-term, debilitating conditions that pose not only a 
burden based on the need to endure the symptoms but also based on the ongoing need to 
address treatment of the condition (May et al., 2014).  The treatment paradigm expands 
further when one chronic, long-term disease leads to additional comorbidities that each 
have specialized healthcare providers, treatments, and treatment schedules and results in 
conditions that are no longer cured, as in the case of infections, but rather must be 
managed for the remainder of the patient’s life span (May et al., 2014).  Previously, 
illness and its cure were predominantly a burden under the purview of the healthcare 
provider (May et al., 2014).  With the change to long-term management, the burden of 
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illness and treatment have been shifted by healthcare providers to the patient, who is 
accountable for managing time, treatments, compliance, and self-care along with the 
other activities of normal life (May et al., 2014).  In order to be managed, the burden 
must be distributed within a patient’s network of friends, family, and caregivers.  These 
issues, then, become the burden not just of the illness but also of the treatment for the 
illness (May et al., 2014).   
NAMD meets the criteria of being a long-term, debilitating disease that requires 
management by a specialized healthcare provider; specialized treatments that forestall or 
prevent progression; and the use of a patient’s network of friends, family, and caregivers 
in order to manage not just the burden of illness (e.g., assistance with activities of daily 
living for prevention of comorbidities that impact quality of life [QOL]) but also the 
burden of treatment (e.g., multiple visits to physicians to receive complicated treatments) 
(May et al., 2014).  By evaluating specific populations of NAMD patients treated with 
aflibercept, my purpose for this study was to assess whether selected health 
characteristics, treatment regimens used, and treatment outcomes differed from what had 
been noted in prior literature.  Further, I evaluated the presence or absence of associations 
between health outcomes, treatment regimens, and treatment outcomes as a secondary 
analysis to determine if the burden of treatment was being assigned to appropriate 
populations. 
Nature of the Study 
This study was a retrospective, contrasted group, cross-sectional, secondary 
analysis of data obtained from three geographically disperse NAMD patient populations 
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wherein the patients had been treated with aflibercept.  I evaluated specific selected 
health characteristics, treatment regimens, and treatment outcomes across the three 
populations to determine whether differences and associations existed.  Advantages of 
using secondary data analysis were that the study was relatively economical and made 
use of data that was available but had not been previously analyzed in the manner 
proposed (Green & Salkind, 2010).  Disadvantages of the secondary analysis design 
included that the fit of the data available for the questions explored were not always 
appropriate, and the quality of the data was not as accurate as data collected as primary 
data (Green & Salkind, 2010).  These data were analyzed by ANOVA, Welch ANOVA, 
c2 analysis, point-biserial analysis, or Spearman’s rank-order correlation of the various 
selected health characteristics, treatment regimens, and treatment outcomes.   
Definitions 
Age-related macular degeneration (AMD): Progressive and chronic ophthalmic 
condition wherein changes to the macula of the eye manifest and have an impact on 
visual function (NEI, 2015b) 
Early Treatment Diabetic Retinopathy Study (ETDRS) charts: Visual acuity 
testing charts utilized in clinical trial applications (Kaiser, 2009) 
Neovascular AMD (NAMD): The later stage of AMD in which new, leaky blood 
vessels grow into the macular region of the eye and cause catastrophic changes in the 
macular tissues resulting in central visual changes that may become permanent blindness 
if not treated (NEI, 2015b) 
Logarithm of the mean angle of resolution (logMAR): the notation that is used to 
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indicate the visual acuity achieved when using ETDRS charts (Kaiser, 2009) 
Macula: A small area near the center of the retina, the health of which is 
necessary for maintaining sharp, central vision that allows individuals to see directly 
ahead (NEI, 2015b) 
Oculus Dexter (OD): Right eye (“Oculus dexter,” 2009) 
Oculus Sinister (OS): Left eye (“Oculus sinister,” 2009) 
Oculus Uterque (OU): Both eyes (“Oculus uterque,” 2009) 
Optical Coherence Tomography (OCT): An imaging technique that uses light to 
provide cross-sectional images of tissues (Fujimoto, Pitris, Boppart, & Brezinski, 2000).  
It is used in ophthalmic indications to visualize the retinal tissue. 
Visual Acuity (VA): The measure of the clarity of an individual’s vision.  This 
measurement specifically deals with the ability of the visual system to resolve spatial 
details (Committee on Disability Determination for Individuals with Visual Impairments, 
National Research Council, Division of Behavioral and Social Sciences and Education, & 
Board on Behavioral, Cognitive, and Sensory Sciences, 2002)  
Assumptions 
My primary assumption for this study was that the data to be gathered at the 
various geographic locations were assumed to be characteristic of the general population 
of patients being treated with aflibercept; therefore, these data could be used to describe 
what the general population characteristics were, what treatment regimens were being 
used, and what treatment outcomes were experienced in these populations.  I also 
assumed that all patients who had NAMD in these retinal practices had been 
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appropriately coded per International Classification of Disease, Version 9 (ICD-9) of 
362.52 (exudative senile macular degeneration of retina).  Finally, I assumed that those 
patients with the ICD-9 code of 362.52, after the approval of aflibercept in 2011, were 
given the opportunity to be treated with aflibercept. 
Scope and Delimitations 
I carried out this study in a specific subpopulation of the AMD general 
population, NAMD.  The rationale for culling the NAMD subgroup from within the 
larger AMD general population was that more treatment options were available in the 
selected population than in the non-NAMD populations (National Institutes of Health 
[NIH], 2014).  Also, the NAMD population was more easily identified as patients were 
actively seeking treatment from medical professionals due to noticeable loss of vision 
(Singer et al., 2012).  While it was important to understand the characteristics of NAMD 
populations and the reality of how patients were identified and treated for NAMD, 
evaluating NAMD populations may advance the larger question of generalizability and 
applicability of clinical research versus general patient populations in other therapeutic 
areas.   
Limitations 
General NAMD population characteristics may be able to be identified easily 
through public databases; however, treatments and treatment outcomes are not typically 
provided in public databases.  As such, it was necessary to identify and gain the consent 
of retina specialists in various parts of the country to capture information to evaluate 
demographic and selected health characteristics as well as treatment regimens and 
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treatment outcomes for NAMD patients treated with aflibercept.  Gaining access to 
electronic medical records (EMR) data that were consistent across the three retinal 
centers limited what could be analyzed in this study.  Consistency in data capture 
between retinal centers was a key element to the design of the study as this was the 
method of establishing the populations as single entities and as a collective.  Without 
consistency, my ability to determine the impact of the independent variables on the 
dependent variable was limited.  To avoid issues of consistency, I evaluated EMR 
systems at retinal practices to determine whether all the proposed variables were present 
and what format was used to capture findings.  A final limitation was that the potential 
associations between selected health characteristics, treatment regimens, and treatment 
outcomes may have been subtle enough so as not to be detected in this study. 
Significance of the Study 
By using secondary analysis of EMR data in a variety of NAMD populations 
treated with aflibercept, I was able to perform evaluations to assist in understanding 
population differences.  Researchers have speculated about different populations of 
NAMD and what the outcome of treatment with anti-VEGF medications might be (Heier, 
2013).  The results of this study could add to the body of knowledge pertaining to how 
aflibercept was being used in retinal practices treating NAMD patients and elucidate the 
impact differences in population outcomes have on personal and public health.  Since 
NAMD treatment makes up a significant portion of the public financial burden in the 
form of Medicare payouts, determining if patients being treated were those that received 
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the greatest benefit from treatment was an important question to answer (Schmier et al., 
2012; Silver, 2014; Stein et al., 2013).   
Significance to Practice 
Significant differences in health characteristics, treatment regimens, and treatment 
outcomes that could be observed between the NAMD populations would aid in defining 
the importance this has on public health and clinical research.  If this findings of this 
study were to show that there were differences existed between the populations 
identified, research into the development of different types of sampling methods, research 
study designs, or methods of translation from clinical research to clinical practice would 
be beneficial (Kessler & Glasgow, 2011; Lenfant, 2003; Sung et al., 2003).  The social 
benefit of creating better testing methods could result in moving clinical research in a 
direction that is more beneficial to a greater portion of the disease population, thereby 
creating better outcomes and stronger evidence-based information on which the public 
can rely (Kessler & Glasgow, 2011; Lenfant, 2003).  Creating more interest in clinical 
research could also increase confidence that the process of clinical research, as a valuable 
part of product development and translation of study findings from clinical research to 
clinical practice, would be more valuable (Drolet & Lorenzi, 2011; Kessler & Glasgow, 
2011; Lenfant, 2003). 
Significance to Social Change 
The positive social change implication of this study was to gain a better 
understanding of how treatment outcomes were affected by selected health characteristics 
and treatment regimens in NAMD.  Having a better understanding could lead to more 
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appropriate information about treatment options for AMD and NAMD patients and could 
inform the design of AMD and NAMD clinical studies to represent more accurately the 
target population in which the therapeutic intervention was to be used.  Further, public 
health initiatives could be designed to identify at-risk AMD and NAMD populations to 
provide education germane to the need for early diagnosis and treatment.  The impact on 
the personal, familial, and societal burdens related to blindness could be ameliorated by 
use of summary information provided to public health organizations, medical 
professionals, and patients. 
Summary  
NAMD is a significant a public health issue since it has a substantial economic 
and health impact both at the individual and population levels.  The aim of this study was 
to assess selected health characteristics, treatment regimens, and treatment outcomes in 
NAMD patients treated with aflibercept in geographically disperse retinal practices in the 
United States to determine whether there were differences in the populations, and 
secondarily, to evaluate what associations existed between the selected variables.  
Ascertaining whether differences existed between populations of NAMD patients was 
clearly of importance in making the appropriate translation of findings from the clinical 
trial phase into the clinical treatment phase.  Treating appropriate patients with 
appropriate interventions could lessen the burden of illness on both patient and the public.  
In Chapter 1, I provided a general overview of the study, including the background of the 
study, the problem statement, the purpose of the study and the associated research 
questions and hypotheses.  The theoretical framework of burden of treatment theory was 
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introduced along with how this theory related to the research problem.  Furthermore, I 
reviewed the nature of the study, definitions, assumptions, scope and delimitations, 
limitations, and significance of the study. In Chapter 2, I will review research relevant to 
NAMD; general population characteristics, including risk factors, comorbidities, and 
genetic profiles; and current therapeutic intervention with anti-VEGF treatments. 
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Chapter 2: Literature Review 
Introduction 
Aflibercept treatment for NAMD has been clinically tested and approved by the 
FDA (2011); however, the selected health characteristics, treatment regimens, and 
treatment outcomes experienced by general patient populations may or may not differ 
from each other and the way the clinical research studies were conducted.  In this study, I 
evaluated three geographically disperse population centers to determine whether there 
were differences between NAMD patients treated with aflibercept, and secondarily, 
whether associations existed between selected health characteristics, treatment regimens, 
and treatment outcomes.  In this chapter, a description of the methods I used to identify 
appropriate literature for this chapter will follow the introduction.  Moreover, I will 
provide a review of literature identified to support the theoretical framework of burden of 
treatment.  The following  section will be a description of the risk factors associated with 
NAMD, the prevalent types of treatment for NAMD, and associated treatment outcomes.  
Additionally, I will present the evaluation of interventions used to treat NAMD including 
treatment regimens, especially as compared to those used in clinical trials.  I will also 
discuss treatment outcomes to elucidate the need to determine how selected health 
characteristics and treatment regimens may impact outcomes.  Finally, a summary of the 
literature review will conclude the chapter. 
Literature Search Strategy 
 This literature review was based on my search for relevant literature using Google 
and Google Scholar search engines as well as direct literature searches using Walden 
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University Library’s Thoreau search of all applicable databases.  The search was focused 
on peer-reviewed, full text articles that were published between the years 2011 through 
2015.  In some cases, it was necessary for me to purchase a full text article when I 
determined that the information the article contained would significantly contribute to the 
literature review.  Websites for the following associations or agencies were also used in 
the literature search: Age-Related Eye Disease Study (AREDS), American Academy of 
Ophthalmology, Association for Research in Vision and Ophthalmology, American 
Foundation for the Blind, U.S. Census Bureau, U.S. Centers for Disease Control and 
Prevention, FDA, National Center for Advancing Translational Science, NEI, and NIH.  
Keywords used alone or in combination included:  age-related eye disease study, age-
related macular degeneration, AMD, anti-VEGF, AREDS, behavior, burden, 
comorbidities, diet, environment, ethics, ethnicity, genetics, neovascular, race, risk 
factor, side effect, translation, treatment, and vascular endothelial growth factor.  These 
searches yielded a wide range of articles that proved to be applicable to this study for 
burden of treatment, AMD, NAMD, treatments, and treatment outcomes.  Since the 
burden of treatment theory was a relatively new concept, fewer articles that pertained to 
this subject were available.  I used a total of nine articles that either discussed the burden 
of treatment or evaluated burden of treatment in a chronic condition or began the 
discussion of developing an instrument to measure the burden of treatment in patient 
populations.  I located approximately 43 appropriate aflibercept treatment covering issues 
including initial results of clinical trials in treatment-naïve subjects, use of aflibercept 
after treatment with other anti-VEGF treatments, use of aflibercept in polyploidal 
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choroidal neovascular AMD, and use of aflibercept in treatment resistant patients.  
Approximately 480 articles were identified that pertained to some aspect of AMD, 
including phases, risks, burden of disease, epidemiology, treatments, and outcomes.  I 
used this information to build a literature-based framework for the study investigating 
different population centers to determine whether there were differences in the selected 
health characteristics, aflibercept treatment regimens, and aflibercept treatment outcomes.  
Theoretical Framework 
The burden of treatment theory aims to facilitate a new understanding of the 
interaction between capacity for action and the work that healthcare systems pass on to a 
patient and his or her relational networks” (May et al., 2014, p. 2).  May, Montori et al. 
(2009) began the discussion of burden of treatment due to the increasing disease burden 
experienced by patients with chronic diseases, which have displaced acute, infectious 
diseases as the main cause of ill health.  Tran et al. (2012) noted that around 45% of the 
general population currently live with at least one chronic disease.  This increases to 
approximately 88% as individuals reach 65 or older (Tran et al., 2012).  May, Montori et 
al. also explained that the burden of disease theory was not only about the disease.  
Bearing the burden of a disease also means bearing the burden of its treatments (May, 
Montori et al., 2009).  A patient is no longer a bundle of symptoms to be cured by acute 
treatment, but rather patients must engage in a multitude of treatment and service 
interactions that require management (May, Montori et al., 2009).  This situation is 
aggravated as patients acquire multiple comorbidities having competing treatments, 
services, outcomes, and impact on each other (May, Montori, et al., 2009).  The 
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imperative of the theory was to identify and address issues “to help alleviate treatment 
burden and tailor treatment regimens to the realities of people’s daily lives” (Sav et al., 
2013, p. 312). 
May et al. (2014) described the process by which burden of treatment theory was 
derived.  The initial focus of the researchers was on normalization process theory in 
which the ways an individual incorporates new ideas, methods, or ways of thinking or 
working into the fabric of his or her life (May, Mair et al., 2009).  Normalization process 
theory was also the foundation of minimally disruptive medicine as described in May, 
Montori et al. (2009).  As normalization theory applies to chronic disease, May et al. 
(2014) explained that chronic disease treatment management must become embedded 
into a patient’s normal daily activities for the patient to manage the lifetime trajectory of 
his or her illness.  Previously, the management of treatment and services related to illness 
were the purview of the physician and his or her staff (May et al., 2014).  The work of 
managing chronic disease has now been transferred to the patient, who may have little 
understanding of the complexities of managing single chronic illness issues let alone 
those associated with multiple multimorbid conditions (May et al., 2014).   
The cumulative complexity model, as elaborated by Shippee, Shah, May, Mair, 
and Montori (2012), supported the issue of the complexity faced by patients with chronic 
multiple multimorbid conditions and was the second conceptual model that was 
formative in the development of burden of treatment theory.  The cumulative complexity 
model deals specifically with how the work of managing healthcare has been transferred 
to patients and how this management was best structured to facilitate his or her meeting 
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the demands of additional healthcare work (Shippee et al., 2012).  Indeed, as the need for 
treatment in multiple multimorbid conditions accumulates, the work that must be 
managed to accomplish all that is necessary with regard to treatment, self-monitoring, 
attention, and coordination can become overwhelming to a patient resulting in confusion, 
nonadherence, poor health outcomes, and inappropriate resource utilization (May et al., 
2014).  Finally, May et al. (2014) described concepts pertaining to “demand, self-care, 
and social networks” (p. 282) as espoused by Blickem et al. (2013), Pickard and Rogers 
(2012), and Vassilev et al. (2013), using the concepts to elaborate how the burden of 
treatment was not a function of just the patient but of the patient’s familial and social 
network and his or her community.  In most cases, patients must find a support network 
to help with the demand of the work of their disease and self-care.  
Some patients endeavor to manage all of the treatments related to chronic disease 
conditions, while other patients may not choose to maintain treatment regimens (May et 
al., 2014).  Although the best course for any patient would seem to be to follow treatment 
regimens prescribed, patients have a variety of meaningful reasons for not doing so (May 
et al., 2014).  Financial issues play a major role in decisions about chronic care; a patient 
may simply not be able to afford the cost of the treatments necessary to support his or her 
illness (May et al., 2014).  Other reasons noted by May et al. (2009) included an inability 
to manage complicated and disruptive dosing schedules.  In some cases, patients may 
have such a wide variety of treatments and dosing schedules that he or she simply cannot 
understand what medications are taken at any given time (May et al., 2014).  
Alternatively, time may be a driving factor in determining whether to adhere to service 
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and treatment schedules (May et al., 2014).  Patients may not be able to take the time 
from other life activities (e.g., work, family) in order to attend doctor or treatment visits 
(May et al., 2014).  Whatever the reason, choosing this path may lead to further decline 
of health and increased need for even more costly treatments, creating a substantial 
personal and public health burden by “wast[ing] of increasingly scarce healthcare 
resources” (Mair & May, 2014, p. 1).  
Eton et al. (2012) performed a qualitative study to begin the process of building a 
patient-reported outcomes instrument to measure burden of treatment.  Patients identified 
for participation in the study were those who were medical outpatients at Mayo Clinic in  
Rochester, MN and had agreed to participate in a medication management program (Eton 
et al., 2012).  All subjects had comorbidities that required significant management of 
treatment, including ophthalmic conditions such as glaucoma and cataracts (Eton et al., 
2012).  From this study, the researchers identified major themes and subthemes that were 
used to inform the elaboration of burden of treatment theory and to develop a conceptual 
framework for a pilot questionnaire pertinent to burden of treatment theory patient-
reported outcomes (Eton et al., 2012). 
Tran et al. (2012) developed the first validated questionnaire that addressed the 
burden of treatment for chronic illness across a multitude of chronic conditions and 
treatment modalities.  In this study, 502 subjects were included in validation of the 
questionnaire that had been derived from literature review as well as from interviews 
(Tran et al., 2012).  The instrument took into account not only treatments for chronic 
diseases but also the ancillary issues of disease surveillance, self-care, and lifestyle 
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changes associated with increases in the burdens of disease and treatment (Tran et al., 
2012).  The findings of the study provided further credence to burden of treatment theory 
as a reliable conceptual framework for addressing chronic and debilitating diseases 
experienced in aging populations (Tran et al., 2012). 
Eton et al. (2013) looked at patient-reported measures of burden of treatment in 
the three chronic diseases of diabetes, chronic kidney disease, and heart failure as a part 
of their systematic review.  Through the review of the available literature, Eton et al. 
identified 57 patient-reported measures in 98 articles relevant to the evaluation of 
treatment burden.  The majority of the articles were identified from the diabetes 
population, but measures were also identified in kidney disease and heart failure articles 
that supported the need to evaluate other chronic diseases (Eton et al., 2013).  This effort 
was undertaken to determine how patient reported measures of treatment burden were 
derived in disease categories and how best to incorporate prior work in the area into a 
more reliable and comprehensive methodology for assessing the burden of treatment 
across diseases (Eton et al., 2013).  The work by Eton et al. expanded on the prior 
qualitative analysis of treatment burden and was to be used in the further refinement of 
the theoretical framework of burden of treatment theory. 
Ridgeway et al. (2014) performed a qualitative study to evaluate factors that may 
impact the burden of treatment for chronic conditions of diabetes, heart failure, and renal 
failure.  The aim of this qualitative study was to identify ways in which the burden of 
treatment can be decreased for patients with multiple multimorbid conditions.  Interviews 
and focus groups were conducted that led to identifying major areas of burden and ways 
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in which the study subjects were able to lessen their impact (Ridgeway et al., 2014).  Five 
major areas were identified as being associated with perception not only of treatment 
burden but also successful management of that burden (Ridgeway et al., 2014).  This 
research clearly identified management strategies that increase the perception of control 
over the disease and the corresponding treatment burden allowed patients to cope more 
effectively and adhere to complicated and time-consuming treatment and service 
regimens (Ridgeway et al., 2014). 
May, Montori et al. (2009) and May et al. (2014) clearly described the criteria that 
set apart diseases as burdensome.  NAMD meets the criteria because it is a long-term, 
debilitating disease and requires therapeutic management by a specialized healthcare 
provider.  Additionally, NAMD requires specialized treatments to forestall or prevent 
progression.  The burden of NAMD not only falls on the patient but also on the patient’s 
network of friends, family, and caregivers in order to manage not just the burden of 
illness (e.g., assistance with activities of daily living for prevention of comorbidities that 
impact quality of life [QOL]) but also the burden of treatment (e.g., multiple visits to 
physicians to receive complicated treatments; May et al., 2014).  With this study, my goal 
was to evaluate specific populations of NAMD patients treated with aflibercept to assess 
whether health characteristic, treatment regimens used, and treatment outcomes differ 
from what has been noted in prior literature.  Additionally, I wanted to evaluate the 
presence or absence of associations between health outcomes, treatment regimens, and 
treatment outcomes to determine if the burden of treatment was being assigned to 
appropriate populations. 
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Age-Related Macular Degeneration 
AMD is a progressive and chronic ophthalmic condition wherein changes to the 
macula of the eye manifest and have an impact on visual function (Lim et al., 2012).  The 
macula is a small area near the center of the retina, and its health is necessary for 
maintaining sharp, central vision that allows individuals to see directly ahead (NEI, 
2015b).  The early phase of AMD occurs when fatty deposits, drusen, collect in the 
macula and present with a characteristically dry appearance (NEI, 2015b).  Individuals 
with this form of AMD do not typically report any significant vision loss, and the 
condition is referred to as dry or atrophic AMD (NEI, 2015b).  Intermediate AMD occurs 
when the RPE displays changes that appear to be a disruption in the color or general 
appearance of the RPE and/or drusen become larger creating more prominent changes in 
visual function (NEI, 2015b).  The late phase of AMD is characterized by either 
increased atrophy in the RPE, choriocapillaris, and photoreceptors, known as GA, or the 
development of new blood vessels into the choroidal space of the macula, known as CNV 
(Lim et al., 2012).  The physical changes in ocular vasculature seen in this phase are not 
healthy structures and tend to leak blood, lipids, and other fluids into the surrounding 
macular tissue causing a fibrous scar buildup (Lim et al., 2012).  The late phase is 
referred to as wet, exudative, or NAMD and is often related to increased levels of VEGF-
A secretion (NEI, 2015b).  VEGF-A is “a diffusible cytokine that plays a key role in the 
formation of CNV lesions through promotion of angiogenesis and vascular permeability” 
(Rakic et al., 2013, p. 1850).  NAMD and GA represent the foremost causes of blindness 
in the world with an estimated global prevalence of 6.8% for early phase AMD and 1.5% 
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for late phase AMD (Dawson et al., 2014; Lim et al., 2012; Rakic et al., 2013; Yuzawa, 
Fujita, Tanaka, & Wang, 2013). 
Based on a recent meta-analysis, Chakravarthy et al. (2010) identified risk factors 
with a consistent and strongly positive association with AMD that included increased 
age, cigarette smoking, cataract extraction, and family history of AMD.  Other risk 
factors with a consistent and moderately positive association included increased body 
mass index, cardiovascular disease history, increased levels of plasma fibrinogen, and 
hypertension (Chakravarthy et al., 2010).  Lim et al. (2012) further noted hyperopic 
refraction and sunlight exposure as significant risk factors. 
An individual with NAMD or GA may not have been diagnosed with the early 
forms of the disease previously, but may present to his or her physician with complaints 
of straight lines becoming wavy or blank/hazy spots in the center of the visual field (i.e., 
metamorphosia) or the inability to see faces of people (Yuzawa et al., 2013).  Once 
identified by these complaints, an ophthalmologist will perform several ophthalmic 
examinations to confirm the presence and extent of NAMD.  These evaluations include 
performing (a) BCVA testing, (b) dilated ophthalmoscopy, (c) Amsler grid testing, (d) 
fluorescein angiography (FA), and (e) OCT (NEI, 2015b).   
The manifestation of NAMD is not only loss of VA in the central field of vision; 
there are concurrent impairments of color vision and contrast sensitivity (Yuzawa et al., 
2013).  Patients with NAMD can often not distinguish colors clearly making it difficult to 
read colored text, and the ability see the contrasts between light and dark may be 
significantly impaired (Yuzawa et al., 2013).  While peripheral vision is not impacted by 
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NAMD, the loss of central vision is significantly disruptive to a patient’s activities of 
daily living including recognizing faces, driving, and reading (Yuzawa et al., 2013). 
Currently no treatments for the early or intermediate, dry forms of AMD exist, 
rather intervention is focused on preventing progression to NAMD (Singer et al., 2012).  
Watchful waiting, an understanding of the changes that might occur, and a plan of action 
for changing vision along with nutritional support are the prophylactic means by which 
individuals manage the earlier phases of AMD.  As reported by the NEI (2015b), 
nutritional support includes Vitamin C, Vitamin E, zinc (as zinc oxide), copper (as cupric 
oxide), and beta-carotene or lutein and zeaxanthin.  The standard of care treatment used 
for advanced NAMD are injections with anti-VEGF drugs (e.g., ranibizumab, 
bevacizumab, aflibercept) that are recombinant, humanized monoclonal antibody 
fragments.  These fragments neutralize active forms of VEGF-A, thereby inhibiting 
proliferation of new blood vessels (Gower, 2012; Rakic et al., 2013).  Anti-VEGF 
injections are approved to be given intravitreally on a monthly basis for at least three 
months (Kovach et al., 2012; Rakic et al., 2013).  After that time, patients may receive 
additional injections as determined by the ophthalmologist (Kovach et al., 2012).  
Outcomes vary with anti-VEGF treatment; however, regaining up to 50% of the vision 
lost in the initial onslaught of neovascularization and leakage has been reported when 
damage is caught early (Lim et al., 2012). 
Risk Factors Associated with NAMD 
The risk factors most commonly associated with NAMD as have been elaborated 
by The Foundation of the American Academy of Ophthalmology are age, genetic 
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predisposition, environment, and behavior (The Foundation of the American Academy of 
Ophthalmology, 2015).  As this is the case, it is important to explore the known risk 
factors to determine whether they are present in the identified patient populations to be 
evaluated in this study.  The risk factors section includes a description of racial/ethnic 
factors, and comorbidities, genetic factors, and behavioral factors. 
Racial/Ethnic Factors 
 NAMD has been characterized as a chronic condition largely affecting Caucasian 
females (Coleman, Chan, Ferris III, & Chew, 2008).  With the advent of better and more 
abundant use of technology, such as FA, fundus photography, indocyanine green 
angiography (ICGA), and OCT, an increase interest in determining whether this profile 
still holds true has been generated (Coscas et al., 2014).  Of special interest is whether 
other types of populations, especially Asian populations, are similar to or different from 
Caucasian populations with regard to risk and prevalence of AMD (Coscas et al., 2014; 
Nakata et al., 2013; Wong et al., 2014).  In a study performed by Nakata et al. (2013), the 
Nagahama study, which was a community based, cross-sectional, prospective cohort 
study, the investigators evaluated the prevalence and characteristics Japanese patients 
with early and late AMD.  The study included 5,595 Japanese individuals aged greater 
than or equal to 50 year of age with gradable AMD recruited from 2008 to 2010 (Nakata 
et al., 2013).  Similar rates of early AMD were observed in this Japanese population as 
compared to Caucasian populations (Nakata et al., 2013).  As well, similar rates of late 
AMD were observed in this Japanese population as compared Caucasian populations in 
individuals less than 70 years of age (Nakata et al., 2013).  At age 70 and higher, the rate 
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of AMD decreased in this Japanese population and was considered to be significantly 
lower than in Caucasian populations (Nakata et al., 2013).  Findings of differences in 
early or late AMD between males and females were not apparent (Nakata et al., 2013).   
In a later retrospective review performed by Coscas et al. (2014), the authors 
evaluated both technology used to assess patients for NAMD and prevalence of subtypes 
of NAMD (i.e., AMD with Type 1 CNV, AMD with Type 1 and 2 CNV, AMD with 
Type 2 CNV, chorioretinal anastomosis, polyploidal choroidal vasculopathy [PCV] 
without CNV, and PCV with Type 1 or 2 CNV) in 94 French and 99 Japanese patients 
with presumed exudative AMD.  PCV was found to be at a higher rate in Japanese 
patients, and Type 1 CNV was found to be at a higher rate in French patients (Coscas et 
al., 2014).  Similarities were noted in Type 2 CNV and chorioretinal anastomosis rates 
between the two populations (Coscas et al., 2014).   
Wong et al. (2014) integrated a large number of population-based AMD studies 
that previously suggested different disease prevalence based on racial or ethnic 
parameters.  By identifying qualified population-based studies using a systematic 
literature review, these investigators analyzed “129,664 individuals (aged 30-97), with 
12,727 cases from 39 studies” (Wong et al., 2014, p. e106).  This large review indicated 
that the global burden of all types of AMD is 8.7% (Wong et al., 2014).  The projection 
for the number of cases in 2020 was estimated at approximately 196 million and by 2040, 
the estimate was approximately 288 million (Wong et al., 2014).  The prevalence of early 
onset AMD was shown to be higher in studies based on European populations than in 
Asian populations; however, late stage AMD prevalence comparison between these two 
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groups was similar (Wong et al., 2014).  The findings from the studies analyzed, 
however, did not consistently show whether the diagnoses included PCV, which is more 
prevalent in Asian populations and may respond differently to treatment (Wong et al., 
2014).  Females of any race were not found to have a strong association with prevalence 
of AMD, and strong evidence refuted previously reported findings that male, Asians who 
smoked were at higher risk than other populations (Wong et al., 2014).  Finally, Wong et 
al. suggested that Asian countries will see the highest increase in all forms of AMD in the 
future despite having a low reported prevalence for the period investigated. 
The findings from these studies are significant for several reasons.  Future 
research should include a significant contribution of patients from Asian populations to 
represent all aspects of the NAMD disease process (Coscas et al., 2014; Nakata et al., 
2013; Wong et al., 2014).  Physicians should be aware that the prevalence of AMD in 
Asian populations approaches that of Caucasian populations in order to provide proper 
diagnosis and treatment (Coscas et al., 2014; Nakata et al., 2013; Wong et al., 2014).  
Differentiating subtypes through the use of available technology could lead to a 
difference in treatment (Coscas et al., 2014; Nakata et al., 2013; Wong et al., 2014). 
Comorbidities 
 Due to the specialty area that ophthalmology has become, Cheung and Wong 
(2014) noted that AMD has been thought of as a localized disease with an association 
with certain risk factors (e.g., smoking, prior cataract surgery, family history).  AMD has 
not been assessed in relation to comorbidities of the whole individual (e.g., hypertension, 
dyslipidemia, cardiovascular disease; Cheung & Wong, 2014).  Based on information 
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from Chou et al. (2013)  and Cheung and Wong, assessing the whole patient in relation to 
comorbidities and association with the risk of AMD is a reasonable approach. 
Chou et al. (2013) performed an analysis on 2012 National Health and Nutrition 
Examination Survey (NHANES) data to determine the source of age-related conditions 
associated with visual impairment among U.S. adults.  The analysis included 5,222 
individual included in the 2012 NHANES who were 40 years of age or older (Chou et al., 
2013).  From this analysis, the investigators were able to determine the prevalence of 
visual impairment was 7.5% and prevalence of visual impairment not due to refractive 
error was 2.5% (Chou et al., 2013).  These findings suggest an estimated population of 9 
million adults in the United States over the age of 40 have some visual impairment (Chou 
et al., 2013).  While a significant portion of the study population whose visual 
impairment could be corrected simply by providing proper refractive correction, of 
greatest concern was the 25% of visual impairment attributed to factors other than 
refractive error (Chou et al., 2013).  Chou et al. reported AMD to be the most commonly 
associated with visual impairment not related to refractive error.  
 Cheung and Wong (2014) performed an extensive literature review of articles 
published from January 1, 2012 through December 31, 2013, examining various systemic 
risk factors to determine which were most highly associated with increased risk of AMD.  
An interesting aspect of the evaluation was that the assessment was originally concerned 
with determining what systemic conditions increased the risk of AMD; however, a 
corollary that AMD may be an indicator of potential manifestation of systemic disease 
was revealed during this investigation (Cheung & Wong, 2014).  The systemic diseases 
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or conditions found to be most highly associated with increased risk of AMD were 
cerebrovascular disease and coronary heart disease (Cheung & Wong, 2014).  
Hypertension and dyslipidemia were shown to have a moderate association with 
increased risk of AMD but the strength and consistency of the association was not as 
apparent from the review of literature (Cheung & Wong, 2014).  Evaluation of the 
potentially correlated systemic risk factors was suggested to be of importance in 
identifying patients at risk for developing NAMD (Cheung & Wong, 2014).  
Systemic therapies were also evaluated by Cheung and Wong (2014).  
Antioxidant supplements such as those found in the AREDS formulations were found to 
result in a reduction in intermediate AMD to advanced AMD by approximately 25% over 
approximately 6 years (Cheung & Wong, 2014).  Aspirin used prophylactically for 
cardiovascular disease may actually increase the risk of AMD although the mechanism of 
the potential increase was not clearly understood (Cheung & Wong, 2014).  Use of statins 
has not been shown to reduce the risk of or progression of AMD consistently in the 
literature (Cheung & Wong, 2014).   
These investigations lend further credence for the need to ascertain whether 
NAMD population treated with anti-VEGF differ with regard to comorbidities and 
whether an association exists with a difference in treatment outcome.  While aging has 
been clearly associated with AMD, subjects with prevalent comorbidities associated with 
immune response would typically be excluded from clinical trials to minimize the issue 
of confounding factors.  While it may not be acceptable to include subjects with 
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significant systemic comorbidities in early clinical trials, later phase clinical trials should 
examine the impact of intervention when significant systemic comorbidities are present.   
Genetics 
Inroads into the understanding of genetic factors associated with NAMD were 
slow moving until 2005 with the identification of complement factor H (CFH) that was 
determined to increase the risk of NAMD significantly (Fritsche et al., 2014).  From this 
beginning, an explosion of research led to the identification of at least 19 alleles 
associated with genetic predisposition for NAMD (Fritsche et al., 2014).  With these 
findings come the prospect of advances not only in understanding of AMD but also of 
more and better treatments for all phases of the disease (Fritsche et al., 2014). 
Hagstrom et al. (2013) evaluated 834 (73%) of the subjects who participated in 
the Comparison of AMD Treatment Trial (CATT) at 43 of the CATT clinical sites.  
These investigators enrolled the identified subjects in a clinical trial to determine whether 
subjects of differing genotypes had different responses to the anti-VEGF therapies, 
ranibizumab and bevacizumab.  Each of the subjects “was genotyped for [single 
nucleotide polymorphisms] rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 
(HTRA1), and rs2230199 (C3)” (Hagstrom et al., 2013, p. e43).  These alleles have been 
noted to have potential impact on the development of AMD; however, no statistically 
significant differences were noted in any of the clinical assessments measured based on 
the genotypes studied, including in the instance of multiple alleles that were present in 
any individual subject (Hagstrom et al., 2013). 
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Nussenblatt et al. (2014) provided investigation into the genetic components of 
AMD and reported, “recent genetic meta-analysis has confirmed 19 loci…that account 
for up to 50% of the heritability of AMD susceptibility” (p. 6).  This finding along with 
environmental factors (e.g., smoking, diet, and weight) “play a crucial role in AMD 
etiology” (Nussenblatt et al., 2014, p. 6).  Further, Nussenblatt et al. noted that both 
genetic and environmental issues need to be considered in the context of aging, as aging 
remains the primary risk factor for AMD.  An aging immune system, or 
immunosenescence, accounts for an increased production of inflammatory cells and a 
decreased ability to clear these types of cells (Nussenblatt et al., 2014).  As such, the 
immune system becomes overloaded and cannot maintain a homeostatic state within the 
body, or specifically the eye (Nussenblatt et al., 2014).  The research by Nussenblatt et al. 
further supports the assertion that AMD is not an isolated disease process but rather is a 
localized manifestation of the immunosenescence of the aging body.   
Cheung and Wong (2014) also noted that genetic markers and pathogenesis 
support the hypothesis that AMD is more than a localized condition.  Inflammation may 
play an important role in the pathogenesis of AMD (Cheung & Wong, 2014).  CFH and 
age-related maculopathy susceptibility 2/HtrA serine peptidase 1 genes have been noted 
to be associated with AMD.  Cheung and Wong concluded, “there is accumulating 
evidence to support the concept that AMD is a localized ocular manifestation of broader 
systemic processes and is closely associated with a range of systemic diseases” (p. 148). 
As a result of the aforementioned studies, the importance of gathering and 
analyzing genotype information in clinical practice and clinical research was established. 
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Collecting genotype information for NAMD patients adds complexity to patient or 
subject visits.  As well, the cost of the testing may prohibitive.  However, the benefit of 
clearly understanding the genetic basis of the disease to develop more appropriate and 
targeted treatments is critical to eradicating this debilitating disease. 
Behavioral Risks 
Behavioral factors that may increase risk of AMD have been enumerated by The 
Foundation of the American Academy of Ophthalmology (2015) and include smoking, 
overexposure to sunlight, and diet.  While smoking and overexposure to sunlight have 
been included in clinical trial investigations for quite some time, the issue of diet is more 
difficult to evaluate.  That stated, a number of investigators have endeavored to evaluate 
the link between AMD and dietary intake (Amirul Islam et al., 2014; Arnold, Jentsch, 
Dawczynski, & Böhm, 2013; Chiu et al., 2014; Christen et al., 2012). 
Christen et al. (2012) performed a long-term, prospective study in physicians to 
determine if Vitamin E and Vitamin C had an impact on the development of AMD.  
Subjects in this study were randomized to either intervention with a regimen of Vitamin 
E and Vitamin C or to a regimen of placebo.  Subjects were asked to report on an annual 
basis regarding the development of AMD (Christen et al., 2012).  If an AMD diagnosis 
was reported, medical records were reviewed to confirm the self-report (Christen et al., 
2012).  After 8 years of evaluation, no differences were found between the incidence of 
AMD in the two groups suggesting that Vitamins E and C were neither harmful nor 
beneficial to the development of AMD (Christen et al., 2012). 
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Arnold et al. (2013) performed a pilot study to determine if a diet high in 
oleaginous extract of Brassica oleracea var. sabellica L. (kale) could impact 
concentration of xanthophyll in both plasma and the macula.  An inverse risk has been 
suggested to exist between xanthophyll concentration and AMD (Arnold et al., 2013).  
Twenty subjects were enrolled in this well-designed and controlled study (Arnold et al., 
2013).  Subject participation included both an intervention period and a washout period 
after intervention (Arnold et al., 2013).  While both plasma and macula levels of 
xanthophyll were elevated during the intervention portion of the study, the effect was not 
present after the 4-week washout (Arnold et al., 2013).  This led Arnold et al. to surmise 
that the “distribution of the xanthophylls in the macula seems to be more dynamic than 
originally assumed”  (p. 1412).  In order to maintain a high level of xanthophylls, 
consumption of kale and other xanthophyll-containing foods would need to be kept at a 
continuously high level (Arnold et al., 2013). 
Amirul Islam et al. (2014) attempted to discover specific dietary intake patterns 
associated with the risk of developing AMD based on primary food intake scale (F1 = 
fruits, F2 = vegetables, F3 = grains, fish, boiled or steamed chicken, and nuts, F4 = red 
meat, F5 = processed foods, and F6 = salad).  No clear delineation of specific food types 
was found to be associated with a higher risk of AMD.  An association with decreased 
risk of AMD seemed to be indicated in subjects with diets higher in fruits, vegetables, 
chicken and nuts than in those with diets higher in red meat consumption (Amirul Islam 
et al., 2014).   
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Chiu et al. (2014) hypothesized that the American dietary pattern put individuals a 
higher risk for the development of AMD.  In a cross-sectional study of subjects 
participating in the AREDS study, Chiu et al., classified 8,103 eyes per the AMD 
classifications developed by AREDS.  These included 2,739 subjects without AMD who 
served as the control group, 4,599 subjects with early AMD, and 765 with late AMD.  By 
evaluating the diets of these subjects, Chiu et al. identified two main dietary types (i.e., 
Oriental and Western) based on the principal components consumed.  Subjects who 
consumed more fresh fruits, vegetables, and fish were considered to follow an Oriental 
dietary pattern (Chiu et al., 2014).  Those subjects who consumed more processed, 
refined, high fat foods and red meat were considered to follow a Western dietary pattern 
(Chiu et al., 2014).  The findings indicated that both dietary patterns are associated with 
early or late AMD (Chiu et al., 2014).  The subjects who consumed food according to an 
Oriental pattern showed reduced odds of developing AMD, with the more adherent 
subjects gaining additional protection (Chiu et al., 2014).  The subjects who consumed 
food according to a Western pattern showed increased odds of developing AMD, with 
additional risk associated with greater consumption of a Western diet (Chiu et al., 2014).   
The findings from these studies are widely varied from direct support for dietary 
impact on both increasing and lowering risk of AMD to no clear support for either a 
beneficial or harmful impact on the development of AMD.  The absence of clearly 
understood mechanisms suggests an importance exists in understanding what type of diet 
patients typically consume to find additional means for lowering the burden of this 
disease.  Collecting information pertaining to weight or dietary intake in ophthalmic 
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clinical practice or clinical research is atypical.  Consequently, coordination between 
several medical disciplines would be necessary to integrate dietary patterns with 
ophthalmic findings. 
Treatments for NAMD 
Treatment of NAMD was exceedingly limited until the relatively recent 
therapeutic approvals of anti-VEGF treatments (Wang & Ohji, 2013).  In the 1980s, the 
treatment option was argon laser photocoagulation (Stein et al., 2013).  For this 
procedure, argon laser was applied to the lesion in the macula, which destroyed the tissue 
but stopped the leakage and destruction of macular cells by essentially cauterizing the 
lesion (Stein et al., 2013).  Continued visual loss was typically ameliorated, but no VA 
gains were evident, and a risk of iatrogenic vision loss was apparent (Stein et al., 2013).   
In 2000, the FDA approved photodynamic therapy (PDT) with verteporfin 
(Visudyne) indicated for subfoveal choroidal neovascularization treatment (Stein et al., 
2013).  Treatment consisted of the injection of verteporfin intravitreally activated by 
exposure to a laser light source in order to cause occlusion of the neovascularization in 
the macula (Curtis et al., 2012).  As with argon laser photocoagulation, PDT can stop the 
progression of neovascularization but does not restore vision lost by the initial growth of 
vessels into the macula (Curtis et al., 2012). 
Treatment for NAMD has changed dramatically over the past 12 years with the 
approval in 2004 of the first of the anti-VEGF treatments, pegatinib (Macugen), and 
approval of ranibizumab (Lucentis) followed in 2006 and aflibercept (Eylea) in 2011 
(Stein et al., 2013).  Although not approved for NAMD, bevacizumab (Avastin) has also 
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been used in for NAMD treatment due to its identification as a much less costly 
alternative the anti-VEGF treatments approved for treatment of NAMD (Stein et al., 
2013).  With the advent of anti-VEGF therapy, no longer was the treatment modality one 
of stopping progression as with PDT; anti-VEGF treatment offered patients the hope of 
regaining some of the vision that had been previously lost (Curtis et al., 2012).  Anti-
VEGF therapy utilizes recombinant, humanized monoclonal antibody fragments to 
neutralize active forms of VEGF-A present in the affected, thereby inhibiting 
proliferation of new blood vessels (Curtis et al., 2012).  Patients experience an 
amelioration of progressive vision loss as well as a recovery of vision over the course of 
continued injections (Curtis et al., 2012).   
Yannuzzi, Patel, Bhavsar, Sugiguchi, and Freund (2014) performed a cross-
sectional, physician survey to determine if anti-VEGF treatments had a negative impact 
on intraocular pressure (IOP).  The study conducted was limited in that it was a cross-
sectional study, and the prevalence of sustained IOP increases were reported by the 
physicians and were not objectively reported by means of IOP data submission and 
analysis (Yannuzzi et al., 2014).  Nonetheless, the findings were interesting in that the 
investigators were able to determine that “higher injection volumes [of anti-VEGF] with 
a rapid injection technique may potentially lead to sustained IOP elevation” (Yannuzzi et 
al., 2014, p. 319).  Utilizing treatment regimen or treatment techniques that are not 
supported by clinical research may lead to negative outcomes in visual function and other 
aspects of ophthalmic disability.  
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Concern has also been expressed regarding the potential for anti-VEGF therapies 
used to treat NAMD to increase risk of negative cerebrovascular and cardiovascular 
effects (Cruess & Giacomantonio, 2014).  This concern came about with the off-label use 
of bevacizumab for NAMD and was based at least in part on the systemic findings of the 
anti-VEGF class of drugs (Cruess & Giacomantonio, 2014).  The systemic findings 
centered around the impact that anti-VEGF therapy had on VEGF in systemic circulation 
that decrease the patency of vessel walls and may cause vessel leakage and destruction of 
tissues (Semeraro et al., 2014).  Thus, investigations were initiated into the issue with 
interesting findings that do not necessarily support the concern for ophthalmic use of 
anti-VEGF treatment.  Semeraro et al. (2014) expressed the concern that intravitreal 
injection with anti-VEGF could have an impact on circulating VEGF systemically; 
however, the evaluation of clinical studies performed by these investigators did not 
support an association between the use of anti-VEGF therapies intravitreally and an 
increased incidence of thromboembolitic events (Semeraro et al., 2014).  The incidence 
of cerebrovascular accident, myocardial infarction, and death was similar in both treated 
and untreated subjects observed (Semeraro et al., 2014). 
Similarly, Ng et al. (2015) expressed concern regarding the use of anti-VEGF 
treatments.  These investigators, too, communicated that although no signals had been 
found to support concern in the products approved for intravitreal injection for NAMD, 
the same could not be said for bevacizumab as it had not been evaluated in the same 
manner as the anti-VEGF treatments approved for NAMD treatment.  As has been 
mentioned, bevacizumab is not approved for intravitreal injection to treat NAMD but is 
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often used off-label due to the lower cost of the product.  Ng et al. evaluated a large 
cohort of subjects who had been treated predominantly with bevacizumab.  The results 
from the analysis of these subjects supported the same conclusions as those of Semeraro 
et al. (2014); no association between the use if intravitreal bevacizumab and increased 
risk of cerebrovascular or cardiovascular events or death was found (Ng et al., 2015). 
Aflibercept Dosing Regimen and Outcomes 
Specifically in NAMD populations, studies of all phases are often performed in 
treatment naïve subjects in order not to have prior treatments obfuscate the findings in the 
trial under investigations (Christen et al., 2012; Gambon et al., 2014; Mazaraki, 
Fassnacht-Riederle, Blum, Becker, & Michels, 2015; Rush, Rush, Aragon II, & Ysasaga, 
2014; Tan et al., 2013).  While approaching clinical studies in this manner may lead to a 
clearer understanding of the mechanisms underlying certain treatments, unless these same 
types of studies are performed in subjects who have been exposed to NAMD treatments, 
there is a knowledge burden that will be faced by the NAMD population that is not naïve 
to anti-VEGF treatments.  External validity of the clinical research study has been 
sacrificed for internal validity.  The ability of an NAMD patient treated with multiple 
therapies and his or her physician to make appropriate treatment decisions is hampered 
by the lack of knowledge about how this additional therapy might impact the patient’s 
health and wellbeing. 
FDA approval for the aflibercept was predicated on two Phase 3, multicenter, 
randomized, active-controlled, clinical trials in which a total of 2,419 subjects were 
randomized to one of the following study arms: 
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• 0.5 mg intravitreal aflibercept dosed monthly 
• 2 mg intravitreal aflibercept dosed monthly 
• 2 mg intravitreal aflibercept dosed every 2 months after 3 initial monthly 
doses 
• 0.5 mg intravitreal ranibizumab dosed monthly (Heier et al., 2012) 
The primary visual outcome used to evaluate the efficacy of aflibercept in NAMD was 
proportion of subjects who maintained gains in BCVA by ETDRS logMAR scoring 
assessed 52 weeks after treatment (Heier et al., 2012).  Anatomical features such as CNV 
lesion size and central retinal thickness were also considered significant outcome 
measures (Heier et al., 2012).  Aflibercept was required to meet a noninferiority standard 
of no less than 10% difference from ranibizumab outcomes (Heier et al., 2012).  All 
aflibercept study arms were considered to be as effective in improving BCVA and 
preventing BCVA loss as ranibizumab (Heier et al., 2012).  Additionally, similar results 
were detected with regard to anatomic measures (Heier et al., 2012).  As a result, the dose 
of aflibercept recommended and approved was “2 mg (0.05 mL or 50 microliters) 
administered by intravitreal injection every 4 weeks (monthly) for the first 12 weeks (3 
months), followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 
months)” (FDA, 2011, sec. 2.2).  This protocol, then, is the standard by which 
populations should be judged when evaluating the safety and efficacy of aflibercept in a 
realistic analysis of clinical practice.  
Both the issue of knowledge burden and confounding may apply to the issue of 
racial diversity in clinical trials.  As has been noted previously by Coscas et al. (2014), 
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Nakata et al. (2013), and Wong et al. (2014), a genetic difference between Caucasian and 
Asian patients with NAMD seemed to exist.  Although race is collected in clinical trials, 
the use of this information is not supportive of the translation of prior epidemiological 
studies of these populations into clinical trials (Thornicroft, Lempp, & Tansella, 2011).  
Statisticians may analyze race between randomized groups in a study to show whether or 
not differences occurred between the numbers and types of individuals randomized to 
each group (Kessler & Glasgow, 2011).  Whether race is then analyzed as a subgroup that 
might have an impact the outcomes seen based on the use of the investigational product is 
unclear.  Because analyses of race/ethnicity and outcome are not conducted, a knowledge 
burden for patients and physicians is produced for determining the best treatment options 
as the potential confounding effect of race has not been adequately investigated.  The 
possibility exists that a patient may be treated with a product that is not particularly 
effective based on the patient’s race (Coscas et al., 2014; Nakata et al., 2013; Wong et al., 
2014).  This increases the burden on the patient both financially and functionally, since 
the visual outcome might not be optimal (Muether, Hermann, Koch, & Fauser, 2011).  
Further, it places an increased burden on healthcare and public health systems, since 
optimal visual function outcomes have not been met and additional outlay of public funds 
may be necessary to support the increased disability of the patient due to blindness 
(Muether et al., 2011; Schmier et al., 2012). 
Rakic et al. (2013) noted that realistic clinical practice outcomes for patients who 
were treated with ranibizumab showed both initial and continuing improvement in a 
prospective, multicenter, observational study of open-label treatment with 0.5 mg of 
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ranibizumab according to realistic clinical practice conditions.  The realistic clinical 
practice paradigm effectively means that the treatment regimen was according to the 
FDA labeling for ranibizumab and not proscribed by a protocol different from the 
labeling (Rakic et al., 2013).  A total of 267 subjects were initially treated in the study 
and were followed for up to 24 months (Rakic et al., 2013).  Investigators were asked to 
follow the normal procedures of treatment, document procedures in medical records, 
request completion of QOL questionnaires by enrolled subjects, and schedule standard 
follow-up visits at 6, 12, and 24 months, which is usual in this indication (Rakic et al., 
2013).  The investigators were asked to follow the treatment regimen recommended by 
the labeling of ranibizumab, which includes monthly injections of 0.5 mg ranibizumab 
for the first 3 months followed by monthly BCVA checks and additional injections based 
on the visual outcome findings (Rakic et al., 2013).  As noted by Rakic et al., (2013), the 
mean number of injections delivered during the loading phase did approximate that noted 
in the labeling (2.5 ± 0.7 injections over 2.5 ± 2 weeks).  This mean, however, does not 
completely depict what transpired with subjects.  Specifically, about half of subjects 
(52.6%) received all three injections, 39.2% received two injections, and 8.2% received 
one injection in the first 3 months (Rakic et al., 2013).  During the follow-up phase of the 
study over the remaining 21 months, re-injection was based on findings of the visual 
outcomes assessments (Rakic et al., 2013).  If the physician diagnosed progression of 
NAMD, additional injections were given (Rakic et al., 2013).  If no progression was 
present, the subject did not receive additional injections (Rakic et al., 2013).  This 
treatment paradigm does differ from that of several of the large, pivotal trials that 
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substantiated the approval of ranibizumab wherein subjects were treated monthly for 
approximately 12 months.  By using the labeled treatment regimen, Rakic et al. (2013) 
noted that the number of injections was significantly lower than that of the clinical trial 
treatment regimen (5.9 ± 3.6 injections over 11.5 ± 9.5 weeks).  These more variable 
treatment conditions based on observation and clinician judgment did lead to positive 
visual outcomes, but the outcomes were not as strongly positive as had been 
demonstrated in the approval-based clinical trials that used a protocol of monthly 
injections (Rakic et al., 2013). 
In an evaluation of the outcomes from a retrospective review of data presented by 
Holekamp et al. (2014), the authors evaluated a large claims database to determine if the 
methods elaborated for treatment regimen in randomized, controlled trials (RCTs) were 
used in clinical practice.  For the anti-VEGF treatments available at the period of time 
investigated, the treatment regimen advocated based on RCTs was monthly monitoring 
and frequent intravitreal injection to maintain the best visual outcomes, which translated 
to approximately monthly injections with anti-VEGF treatment in the RCTs (Holekamp 
et al., 2014).  This study evaluated over 19,000 patients with claims based on new 
diagnoses.  The findings for the period investigated (i.e., 2006–2007) for ranibizumab 
and bevacizumab use were quite different from what had been shown to be safe and 
effective in RCTs.  Rather than the twelve injections supported by the approval-based 
clinical studies, patients received a mean annual number of 4.6 injections in the 
bevacizumab-treated group and 6.9 injections in the ranibizumab-treated group. 
(Holekamp et al., 2014).  Further, these patients received substantially fewer follow up 
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clinic visits to assess visual outcomes and adjust treatment as needed.  Although these 
investigators were not able to determine the direct effect on visual outcomes based on 
their use of the claims data, almost certainly an addition burden was placed on patients 
who were not treated according to the established treatment regimen (Holekamp et al., 
2014).  
Translating procedures and findings from both clinical trials and epidemiological 
studies to clinical practice is a change that needs to occur in our healthcare paradigm for 
the best outcomes for patients and physicians.  The level of clinical care provided by the 
investigators evaluated in Rakic et al. (2013) seems to have surpassed that of those 
evaluated in Holekamp et al. (2014).  This difference would suggest a decline in 
outcomes would be more profound as noted by the information provided by Rakic et al. 
(2013). 
Summary  
 Aflibercept treatment has been approved for marketing in NAMD patients by the 
FDA; however, the use of this intervention and outcomes associated with its use in 
populations that differ from the clinical research population have not been well-
characterized.  In this study, my goal was to evaluate whether differences existed 
between three retinal practice populations of NAMD patients treated with aflibercept 
with regard to selected health characteristics, treatment regimens, and treatment 
outcomes.  A secondary analysis evaluated associations between the selected variables.  
The literature reviewed supported that several different variables (i.e., race/ethnicity, 
comorbidities, genetic factors, and behavioral factors) were associated with an increased 
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risk of NAMD but may not be evaluated in NAMD clinical trials.  As well, the literature 
review supported the need for examination of different population centers to determine if 
differences or associations existed between the populations with regard to selected health 
characteristics, treatment regimens, and treatment outcomes.  The research methodology 
employed could help to fill a gap in the literature related to the aflibercept treatment 
regimens and outcomes and could extend the body of knowledge pertaining to aflibercept 
treatment and NAMD outcomes in a variety of populations.  I will discuss the 
methodology for this study in Chapter 3. 
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Chapter 3: Research Method 
Introduction 
In this study, I evaluated three geographically disperse private retinal practices to 
determine if differences between NAMD patients treated with aflibercept existed, and 
secondarily, whether associations regarding selected health characteristics, treatment 
regimens, and treatment outcomes existed.  In this chapter, I will provide details of the 
specifics for the research methodology used, including the research design and rationale, 
target population, sample and sampling procedures, and data collection procedures.  I will 
also elaborate the operationalization of all variables in the study, the data analysis plan, 
and any threats to the validity of the study.  Finally, I will review ethical considerations 
and the implications of these on the data collection method. 
Research Design and Rationale 
In this study, I used a retrospective, cross-sectional study design wherein the 
categorical groups of NAMD patients treated with aflibercept from three geographically 
disperse private retinal practices (grouping variable) were contrasted with respect to 
demographic and selected health characteristics (independent variables), treatment 
regimens (independent variables), and treatment outcomes (dependent variables).  As 
noted by Frankfort-Nachmias and Nachmias (2007), using contrasting groups creates a 
situation wherein “straightforward comparative statistical analyses” (p.119) can be 
performed on the various dependent variables under observation.  Campbell and Stanley 
(1963) clarified that contrasting group research is not the same as the pretest-posttest 
control group design in that subjects in a contrasting group project could not be randomly 
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assigned to the categorical groups described.  For this study, I used categorical groups 
rather than the randomization of subjects since both the primary objectives involved 
categories by which the groups are naturally divided and into which individuals could not 
be randomized (Campbell & Stanley, 1963; Frankfort-Nachmias & Nachmias, 2007).  I 
collected the data for this study by traveling to one of the retinal practices to work 
directly with the personnel who manage the EMR system.  For the other two practices, 
the data were available by direct access to the EMR system.  By using direct interaction 
with the selected retinal practices, I gathered the most appropriate information in the most 
efficient manner.  Time constraints were a limiting issue for the personnel at the retinal 
practices with a direct impact on the timeliness of gathering data.  Travel costs were also 
prohibitive in gaining access to data at the physician’s practice that was in California.  
The result was that data for fewer subjects were made available at this practice. 
Population 
 The population for this study included patients identified at participating retinal 
centers who had a diagnosis code in ICD-9 of 362.52 (exudative senile macular 
degeneration of retina).  Specifically, I included patients in the study from three retina 
centers located in three population centers in the United States, based on review of EMR, 
if they meet the following criteria: 
• Diagnosis of NAMD in at least one eye during the period of 2011 to 2014. 
• Treatment with aflibercept intravitreal injections after approval in 2011. 
• At least one BCVA and OCT assessment within the approximately 1-month 
period prior to treatment with aflibercept. 
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• At least three BCVA and OCT assessments during the approximately 1-year 
period following treatment with aflibercept. 
Sampling and Sampling Procedures 
I used a one-way ANOVA to evaluate continuous variables (i.e., age, number of 
ocular and systemic comorbidities, number of days between initial NAMD diagnosis to 
the first aflibercept treatment, baseline VA, baseline OCT, the average number of days 
between treatments, the average number of treatments giving during the approximately 1-
year period following the first aflibercept treatment in the study eye, change from 
baseline VA, and change from baseline OCT) to determine whether differences were 
present between the three geographically disperse retinal practices.  c2 analysis was used 
to evaluate the categorical variable of gender to determine if differences existed in this 
variable between the three retinal practices.  Associations were evaluated using 
Spearman’s rank-order correlation for the comparison of two continuous variables and 
point-biserial analysis for comparison of the combination of categorical and continuous 
variables.  When assumptions were violated, I performed the appropriate nonparametric 
testing as deemed appropriate.  This included using a Welch one-way ANOVA with post 
hoc testing for variables in which the homogeneity of variance assumption was violated. 
As noted by Sheperis (2013), most researchers accept a power of 0.80 (80%) 
when determining sample size estimates; however, clinical research studies typically 
depend on a power of .90 to .95 (90% to 95%) for studies for which FDA approval for 
marketing is sought.  The proposed analysis for this study was based on 95% power 
calculation.  With this information and estimating a modest effect size of 0.25, a sample 
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size of 252 participants and two degrees of freedom in the numerator and 249 degrees of 
freedom in the denominator resulted in 95.1% chance of detecting a statistically 
significant difference between the three groups (i.e., retinal practices) at a = 0.05 using a 
fixed effects, omnibus, one-way ANOVA.  The sample size estimate was calculated 
using G*Power, version 3.1.9.2 (Faul, Erdfelder, Buchner, & Buchner, 2007). 
I chose a purposive sampling method for the general NAMD patient population in 
order to capture data for all patients identified within the period specified previously at 
each of the retina specialists’ offices.  Each site provided a de-identified data set with the 
appropriate patients included.  Since three retinal practices were identified, the sample 
was proposed to be divided by the number of practices and data from approximately 84 
patients was to be collected at each site (N = 252).  Patients were: (a) identified working 
from the most recently diagnosed patients, (b) with at least one year of follow-up, (c) 
starting at 2015 and working backward in time until the appropriate number of patients 
had been identified.  The proposed accrual was a total of 84 patients identified at each 
site.   
Procedures for Recruitment, Participation, and Data Collection 
For the general NAMD population, three retinal specialist sites located in various 
geographic locations within the United States gave me permission to review patient EMR 
under strict adherence to Health Insurance Portability and Accountability Act (HIPAA) 
of 1996 rules pertaining to the privacy of patient medical information.  I conducted my 
review to identify those patients at the retinal practices who met the first of the criteria 
(i.e., having NAMD diagnosis in at least one eye during the period of 2011 to 2014).  
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Once appropriate patients were identified within the EMR database, I separated those 
patients who met the remaining criteria from the whole of the EMR records for de-
identification.  Only those fields necessary for analysis were collected.  Fields that were 
not captured in the final database included:  name, work place name, personal and work 
addresses, personal and work telephone numbers, personal and work e-mail addresses, 
insurance, and any other information that might lead back to the individual’s 
identification.  Due to the retrospective nature of this study and the fact that patient 
information was de-identified, there was no need for me to collect informed consent for 
use of the data. 
Operationalizing Variables 
To operationalize the data, a definition of each of the variables was necessary.  
The variables that I proposed to collect in the general population dataset are described in 
greater detail in Table 1. 
Table 1 
Planned Variables and Coding for General NAMD Population 
Variable Definition Nature of 
Variable 
Coding of Variable 
Patient ID De-identified 
Patient 
Identification 
Number 
Text Site 1 = 1001 – 1999 
Site 2 = 2001 – 2999 
Site 3 = 3001 – 3999 
 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
Gender Patient’s Gender Dichotomous 1 = Male 
2 = Female 
Race/Ethnicity Patient’s reported 
race or ethnicity 
Categorical 1 = White 
2 = Black or African 
American 
3 = Hispanic or Latin 
4 = American Indian and 
Alaska Native 
5 = Asian 
6 = Native Hawaiian and 
Other Pacific Islander 
7 = Multiple Race/Ethnicity 
(check all that apply) 
1 = White 
2 = Black or African 
American 
3 = Hispanic or Latin 
4 = American Indian and 
Alaska Native 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
   5 = Asian 
6 = Native Hawaiian and 
Other Pacific Islander 
Age Age in years 
calculated from 
the date of birth 
compared to the 
date of the dataset 
Numeric __.__ years 
Iris Color The predominant 
color of the iris in 
each eye 
Categorical 1 = Gray 
2 = Blue 
3 = Green 
4 = Hazel 
5 = Brown 
6 = Black 
7 = Other 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
Ocular 
Comorbidities 
Does the patient 
have any of the 
following ocular 
comorbidities? 
(check all that 
apply) 
Categorical 1 = Cataract 
2 = Cytomegalovirus Retinitis 
3 = Diabetic Macular Edema 
4 = Glaucoma or Ocular 
Hypertension 
5 = Keratoconus 
6 = Posterior Vitreous 
Detachment 
7 = Retinal Detachment 
8 = Retinal Vein Occlusion 
9 = Uveitis 
10 = N/A 
Systemic 
Comorbidities 
Does the patient 
have 
comorbidities 
associated with 
any of the 
following body  
Categorical 1 = Circulatory 
2 = Digestive 
3 = Endocrine 
4 = Immune 
5 = Integumentary 
6 = Muscular 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
 systems? (check 
all that apply) 
 7 = Nervous  
8 = Reproductive 
9 = Respiratory 
10 = Skeletal 
11 = Urinary 
12 = N/A 
Comorbidities If yes, diagnosis 
associated with 
body system 
Text Text entered in this field will 
be coded based on the Medical 
Dictionary for Regulatory 
Activities (MedDRA). 
Smoking Does the patient 
report a history of 
smoking? 
Dichotomous 1 = No 
2 = Yes 
Alcohol Abuse Does the patient 
report a history of 
alcohol abuse 
Dichotomous 1 = No 
2 = Yes 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
Genotype Does the 
physician report 
either of the 
genotypes for the 
patient? 
Categorical 1 = rs11200638 of the HTRA1 
gene 
2 = rs10611710 of the CFH 
gene 
3 = Other 
4 = N/A 
Eye Involved Which eye(s) 
have a diagnosis 
of NAMD 
Categorical 1 = OD 
2 = OS 
3 = OU 
Diagnosis Date Date the patient’s 
ophthalmologist 
diagnosed 
NAMD for each 
eye 
Date ODDiag = DD MON YYYY 
OR 
OSDiag = DD MON YYYY 
OUDiag = DD MON YYYY 
Length of 
Diagnosis 
Calculated from 
the date of 
diagnosis to the 
date of the dataset 
Numeric ODLength = __.__ years 
OSLength = __.__ years 
OULength = __.__ years 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
Dates of 
Treatment 
Aflibercept 
treatment dates 
for the study eye  
Date ODTrt1 = DD MON YYYY 
OR 
OSTrt1 = DD MON YYYY 
OUTrt1 = DD MON YYYY 
Study Eye The eye which 
received the first 
injection of 
aflibercept 
Categorical 1 = OD 
2 = OS 
Baseline BCVA BCVA prior to 
receiving initial 
aflibercept 
treatment for the 
study eye 
Number ODVABL = _.__ 
OSVABL = _.__ 
 
Snellen BCVA will be 
converted to ETDRS logMAR 
equivalent 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
Follow-Up 
BCVA 
BCVA associated 
with each 
injection of 
aflibercept 
Number ODVA1 = _.__ 
OR 
OSVA1 = _.__ 
 
Snellen BCVA will be 
converted to ETDRS logMAR 
equivalent 
Baseline OCT Central retinal 
thickness prior to 
receiving initial 
aflibercept 
treatment 
Number ODOCTBL = ___._ µm 
OSOCTBL = ___._ µm 
Follow-Up OCT Central retinal 
thickness 
associated with 
each injection of 
aflibercept 
Number ODOCT1 = ___._ µm 
OSOCT1 = ___._ µm 
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Table 2 is a representation of the proposed general NAMD population data set. 
Table 2 
Example of Data Set for General NAMD Population 
Variable Definition Coding of Variable 
Patient ID De-identified Patient 
Identification Number 
1001 
Gender Patient’s Gender 2 
Race/Ethnicity Patient’s reported race or 
ethnicity 
1 
Age Age in years calculated from 
the date of birth compared to 
the date of the dataset 
65 
Iris Color  The predominant color of the 
iris in each eye 
ODIris = 2 
OSIris = 2 
Ocular Comorbidities Does the patient have any of 
the following ocular 
comorbidities? (check all that 
apply) 
1 
4 
 (table continues)  
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 Variable Definition Coding of Variable 
Systemic 
Comorbidities 
Does the patient have 
comorbidities associated with 
any of the following body 
systems? (check all that apply) 
1 
8 
9 
10 
Comorbidities If yes, diagnosis associated 
with body system 
1 = Systemic Hypertension 
8 = Hysterectomy 
9 = Chronic Obstructive 
Pulmonary Disease 
10 = Osteoarthritis 
Smoking Does the patient report a 
history of smoking? 
2 
Alcohol Abuse Does the patient report a 
history of alcohol abuse 
1 
Genotype Does the patient either of the 
genotypes? 
3 
Eye Involved Which eye(s) have a diagnosis 
of NAMD 
1 
 
Diagnosis Date Date the patient’s 
ophthalmologist diagnosed 
NAMD for each eye 
ODDiag = 16 Nov 2012 
 
(table continues)  
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Variable Definition Coding of Variable 
Length of Diagnosis Calculated from the date of 
diagnosis to the date of the 
dataset 
ODLength = 2.72 years 
 
Study Eye The eye which received the 
first injection of aflibercept 
1 = OD 
Dates of Treatment Aflibercept treatment dates for 
each eye treated 
ODTrt1 = 19 Nov 2012 
ODTrt2 = 24 Dec 2012 
ODTrt3 = 21 Jan 2013 
ODTrt4 = 18 Feb 2013 
ODTrt5 = 22 Apr 2013 
ODTrt6 = 22 Jul 2013 
ODTrt7 = 21 Oct 2013 
Baseline BCVA BCVA prior to receiving 
initial aflibercept treatment for 
each eye treated 
ODVABL = 1.00 
 
 
(table continues)  
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Variable Definition Coding of Variable 
Follow-Up BCVA BCVA associated with each 
injection of aflibercept 
ODVA1 = 0.98 
ODVA2 = 0.72 
ODVA3 = 0.60 
ODVA4 = 0.56 
ODVA5 = 0.50 
ODVA6 = 0.50 
ODVA7 = 0.54 
Baseline OCT Central retinal thickness prior 
to receiving initial aflibercept 
treatment 
ODOCTBL = 608 
 
Follow-Up OCT Central retinal thickness 
associated with each injection 
of aflibercept 
ODOCT1 = 606 
ODOCT2 = 580 
ODOCT3 = 560 
ODOCT4 = 500 
ODOCT5 = 460 
ODOCT6 = 445 
ODOCT7 = 450 
 
The patient data noted in Table 2 represents a 65-year-old, Caucasian, female, with blue 
irides diagnosed with NAMD in the right eye (OD) on November. 16, 2008 (2.72 years 
prior to data collection).  The patient was also diagnosed with ocular conditions of 
67 
 
cataract and glaucoma and systemic conditions of hypertension, hysterectomy, chronic 
obstructive pulmonary disease, and osteoarthritis.  The patient received seven treatments 
OD (i.e., the study eye) with aflibercept between the dates of November. 19, 2012 and 
October 21, 2013, with baseline BCVA of 1.00 logMAR, which improved to 0.54 
logMAR by the final treatment and baseline central retinal thickness of 608 µm, which 
improved to 450 µm by the final treatment. 
Data Analysis Plan  
The research questions for this study were: 
Research Question 1: Were there significant differences between selected health 
characteristics of populations of NAMD patients treated with aflibercept in three 
private, retinal practices in geographically disperse population centers in the 
United States? Health characteristic variables included: age, gender, number of 
ocular comorbidities, number of systemic comorbidities, number of days between 
NAMD diagnosis and first treatment with aflibercept in the study eye, baseline 
BCVA, baseline OCT. 
H01: µ1=µ2 
There were no differences in proportions between selected health 
characteristics of populations of NAMD patients treated with aflibercept 
in three private, retinal practices in geographically disperse population 
centers in the United States. 
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Ha1: µ1≠µ2 
There were differences in proportions between selected health 
characteristics of populations of NAMD patients treated with aflibercept 
in three private, retinal practices in geographically disperse population 
centers in the United States. 
My analysis for this research question included several different comparisons. 
The categorical variable of gender was compared using the incidence of males and 
females at each retinal practice using a two-tailed analysis with a = 0.05.  I used a c2 test 
of homogeneity to compare the variable incidence in each of the three retinal practices to 
determine if differences in gender existed between the practices. The continuous 
variables of age, number of ocular comorbidities, number of systemic comorbidities, 
number of days between NAMD diagnosis and first treatment with aflibercept in the 
study eye, baseline BCVA, and baseline OCT were compared using mean values for each 
variable for each eye treated using a two-tailed analysis with a = 0.05.  I used a one-way 
ANOVA to compare the mean values of each variable in each of the three retinal 
practices to determine differences exist between the practices. 
Research Question 2: Were there significant differences between aflibercept 
treatment regimens used to treat NAMD patient in three private, retinal practices 
in geographically disperse population centers in the United States? Treatment 
regimen variables included: average number of aflibercept treatments injections 
received during one year from initial aflibercept treatment and average number of 
days between aflibercept treatments. 
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H02: µ1=µ2 
There were no differences in the aflibercept treatment regimens used to 
treat populations of NAMD among patients at three private, retinal 
practices in geographically disperse population centers in the United 
States. 
Ha2: µ1≠µ2 
There were differences in aflibercept treatment regimens used to treat 
populations of NAMD among patients at three private, retinal practices in 
geographically disperse population centers in the United States. 
My analysis for this research question was a comparison of the two continuous 
variables.  This was accomplished using mean values for each variable for the study eye 
treated using a two-tailed analysis with a = 0.05.  I used a one-way ANOVA to compare 
the mean values of each variable in each of the three retinal practices to determine 
differences exist between the practices. 
Research Question 3: Were there significant differences between aflibercept 
treatment outcomes reported for NAMD patients in the three private, retinal 
practices in geographically disperse population centers in the United States? 
Treatment outcome variables included: average change from baseline in BCVA 
and average change from baseline in OCT. 
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H03: µ1=µ2 
There were no differences between aflibercept treatment outcomes 
reported for NAMD patients in three private, retinal practices in 
geographically disperse population centers in the United States. 
Ha3: µ1≠µ2 
There were differences between aflibercept treatment outcomes reported 
for NAMD patients in three private, retinal practices in geographically 
disperse population centers in the United States. 
My analysis for this research question was a comparison of the two continuous 
variables.  This was accomplished using mean values for each variable for the study eye 
treated using a two-tailed analysis with a = 0.05.  I used a one-way ANOVA to compare 
the mean values of each variable in each of the three retinal practices to determine 
differences exist between the practices. 
Research Question 4: What associations existed between selected health 
characteristics and aflibercept treatment regimens used to treat NAMD patients in 
three private, retinal practices in geographically disperse population centers in the 
United States? 
H04: ßĸ=0 
There were no associations between selected health characteristics and 
aflibercept treatment regimens used to treat NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
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Ha4: ßĸ≠0 
There were associations between selected health characteristics and 
aflibercept treatment regimens used to treat NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
My analysis for this research question included the use of comparisons and 
correlations. I compared the categorical variable of gender using the incidence of males 
and females compared to each of the treatment regimen variables at each retinal practice 
using a two-tailed analysis with a = 0.05.  Point-biserial correlation was used to 
determine if associations existed between gender and treatment regimens. The continuous 
variables of age, number of ocular comorbidities, number of systemic comorbidities, 
number of days between NAMD diagnosis and first treatment with aflibercept in the 
study eye, baseline BCVA, and baseline OCT were compared using mean values for each 
variable for each eye treated using a two-tailed analysis with a = 0.05.  I also used 
Spearman’s correlation to determine if associations existed between the selected health 
characteristics and treatment regimens. 
Research Question 5: What associations existed between selected health 
characteristics and aflibercept treatment outcomes reported for NAMD patients in 
three private, retinal practices in geographically disperse population centers in the 
United States? 
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H05: ßĸ=0 
There were no associations between selected health characteristics and 
aflibercept treatment outcomes reported for NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
Ha5: ßĸ≠0 
There were associations between selected health characteristics and 
aflibercept treatment outcomes reported for NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
I analyzed data for this research question in the following ways. The categorical 
variable of gender was compared using the incidence of males and females compared to 
each of the treatment regimen variables at each retinal practice using a two-tailed analysis 
with a = 0.05.  I used a point-biserial correlation to determine if associations existed 
between gender and treatment outcomes. The continuous variables of age, number of 
ocular comorbidities, number of systemic comorbidities, number of months since NAMD 
diagnosis, baseline BCVA, and baseline OCT were compared using mean values for each 
variable for each eye treated using a two-tailed analysis with a = 0.05.  I used 
Spearman’s correlation to determine if associations existed between the selected health 
characteristics and treatment outcomes. 
Research Question 6: What association existed between aflibercept treatment 
regimens used and aflibercept treatment outcomes reported for NAMD patients in 
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three private, retinal practices in geographically disperse population centers in the 
United States? 
H06: ßĸ=0 
There were no associations between aflibercept treatment regimens used 
and aflibercept treatment outcomes reported for NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
Ha6: ßĸ≠0 
There were associations between aflibercept treatment regimens used and 
aflibercept treatment outcomes reported for NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
My analysis for this research question was a comparison of the two continuous 
treatment regimen variables and the two continuous treatment outcomes variables.  This 
was accomplished using mean values for each variable for the study eye treated using a 
two-tailed analysis with a = 0.05.  I used Spearman’s correlation to determine if 
associations existed between the selected health characteristics and the treatment 
outcomes.  
Analyses were conducted using IBM SPSS Statistics 23.  Data were imported 
from site EMR files and entered directly into the final SPSS database.  The various 
independent variables were classified into three groups based on the ophthalmic practice 
from which the data were obtained (i.e., CA, KY, and OH).  Data were assessed for 
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outliers, normality, missing data, multicollinearity, and homogeneity of variance.  Means 
and standard deviations were reported for each variable from the secondary analysis of 
the NAMD populations.  Results of the ANOVA analyses were reported as F-statistic 
with the associated between groups degrees of freedom followed by the within groups 
degrees of freedom and the p-value.  Results of the Spearman’s correlation were reported 
as the correlation coefficient, rs, with the number of degrees of freedom followed by the 
p-value. 
Threats to Validity  
 Threats to validity include issues that jeopardize the ability of a researcher to 
draw thorough and appropriate conclusions based on the data collected (Frankfort-
Nachmias & Nachmias, 2007).  Internal validity refers to the way in which studies are 
designed and the manner in which data are collected (Frankfort-Nachmias & Nachmias, 
2007).  For this study, threats to internal validity occurred with respect to the general 
NAMD population selection.  This study was not randomized; therefore, it was necessary 
identify patients based on diagnosis, treatment, and outcome measure availability in the 
EMR systems of the participating sites.  External validity deals with how well the results 
of the study can be translated to a larger population (Frankfort-Nachmias & Nachmias, 
2007).  Generalizability from this study to other therapeutic interventions in NAMD and 
in ophthalmology should be robust but may be questionable for other medical conditions.  
Statistical conclusion validity was based on several issues pertaining to detecting errors 
due to the analysis and/or data being analyzed.  This study was initially designed to have 
95% power to detect a Type 1 error.  As well, the assumptions associated with analysis 
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by ANOVA were tested to make certain that the inferences made, based on the analysis 
of these data, were appropriate.  As data were collected it became apparent that the 
required number of patients (i.e., 252) to support the 95% power computation were not 
available at the retinal practices identified.  A total of 199 patients were identified, which 
lowered the power of the study to detect a Type 1 error to 90%. 
Ethical Procedures  
 All data collected in this study were de-identified prior to analysis as suggested by 
the HIPAA.  Data use agreements and letters of cooperation were completed with each of 
the three retinal practice physicians in order to gain access to the EMR data for patients at 
each office (Appendices A–C).  As well, all applicable laws regarding privacy and 
confidentiality were followed. This study was submitted to the Walden University 
Institutional Review Board (IRB) for approval (IRB Approval Number 01-20-16-
0246251) to ascertain whether the study complied with the ethical standards of the 
university and U.S. federal regulations.  Data were housed on a password-protected 
computer with limited access by me only.  Data will be destroyed 5 years after 
completing the study. 
Summary  
This study was a retrospective, contrasted-groups, cross-sectional study design 
wherein the categorical groups of three NAMD patient populations were contrasted with 
respect to selected health characteristics, treatment regimens, and treatment outcomes.  
The study was focused on the research question of whether disparities existed between 
the three geographically disperse NAMD patient populations. NAMD patient population 
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data were collected from three retina specialists located around the United States.  
Secondary data analyses were performed on variables from this data collection to 
determine the means and standard deviations in the general NAMD patient population.  
One-way ANOVA and c2 analyses were performed to determine whether there were 
differences between each of the retina practices with respect to selected health 
characteristics, aflibercept treatment regimens, and aflibercept treatment outcomes.  
Spearman’s correlation and point-biserial correlation were performed to determine 
whether associations existed between selected health characteristics, aflibercept treatment 
regimens, and aflibercept treatment outcomes.  I will document the results of these 
analyses in Chapter 4, and Chapter 5 will be used to elaborate how the results from this 
study relate to other previously published literature.  
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Chapter 4: Research Method 
Introduction 
The purpose of this study was to evaluate whether significant differences existed 
regarding selected health characteristics, treatment regimens, and treatment outcomes for 
patients with NAMD treated with aflibercept from three private, retinal practices in 
geographically disperse population centers in the United States.  The research questions 
and hypotheses that guided this study were: 
Research Question 1: Were there significant differences between selected health 
characteristics of populations of NAMD patients treated with aflibercept in three 
private, retinal practices in geographically disperse population centers in the 
United States? Health characteristic variables included: age, gender, number of 
ocular comorbidities, number of systemic comorbidities, number of days between 
NAMD diagnosis and first treatment with aflibercept in the study eye, baseline 
BCVA, and baseline OCT. 
H01: µ1=µ2 
There were no differences in proportions between selected health 
characteristics of populations of NAMD patients treated with aflibercept 
in three private, retinal practices in geographically disperse population 
centers in the United States. 
Ha1: µ1≠µ2 
There were differences in proportions between selected health 
characteristics of populations of NAMD patients treated with aflibercept 
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in three private, retinal practices in geographically disperse population 
centers in the United States. 
Research Question 2: Were there significant differences between aflibercept 
treatment regimens used to treat NAMD patient in three private, retinal practices 
in geographically disperse population centers in the United States? Treatment 
regimen variables included: average number of aflibercept treatments injections 
received during one year from initial aflibercept treatment and average number of 
days between aflibercept treatments. 
H02: µ1=µ2 
There were no differences in the aflibercept treatment regimens used to 
treat populations of NAMD among patients at three private, retinal 
practices in geographically disperse population centers in the United 
States. 
Ha2: µ1≠µ2 
There were differences in aflibercept treatment regimens used to treat 
populations of NAMD among patients at three private, retinal practices in 
geographically disperse population centers in the United States. 
Research Question 3: Were there significant differences between aflibercept 
treatment outcomes reported for NAMD patients in the three private, retinal 
practices in geographically disperse population centers in the United States? 
Treatment outcome variables included: average change from baseline in BCVA 
and average change from baseline in OCT. 
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H03: µ1=µ2 
There were no differences between aflibercept treatment outcomes 
reported for NAMD patients in three private, retinal practices in 
geographically disperse population centers in the United States. 
Ha3: µ1≠µ2 
There were differences between aflibercept treatment outcomes reported 
for NAMD patients in three private, retinal practices in geographically 
disperse population centers in the United States. 
Research Question 4: What associations existed between selected health 
characteristics and aflibercept treatment regimens used to treat NAMD patients in 
three private, retinal practices in geographically disperse population centers in the 
United States? 
H04: ßĸ=0 
There were no associations between selected health characteristics and 
aflibercept treatment regimens used to treat NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
Ha4: ßĸ≠0 
There were associations between selected health characteristics and 
aflibercept treatment regimens used to treat NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
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Research Question 5: What associations existed between selected health 
characteristics and aflibercept treatment outcomes reported for NAMD patients in 
three private, retinal practices in geographically disperse population centers in the 
United States? 
H05: ßĸ=0 
There were no associations between selected health characteristics and 
aflibercept treatment outcomes reported for NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
Ha5: ßĸ≠0 
There were associations between selected health characteristics and 
aflibercept treatment outcomes reported for NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
Research Question 6: What association existed between aflibercept treatment 
regimens used and aflibercept treatment outcomes reported for NAMD patients in 
three private, retinal practices in geographically disperse population centers in the 
United States? 
H06: ßĸ=0 
There were no associations between aflibercept treatment regimens used 
and aflibercept treatment outcomes reported for NAMD patients in three 
81 
 
private, retinal practices in geographically disperse population centers in 
the United States. 
Ha6: ßĸ≠0 
There were associations between aflibercept treatment regimens used and 
aflibercept treatment outcomes reported for NAMD patients in three 
private, retinal practices in geographically disperse population centers in 
the United States. 
The research questions for this study were designed to evaluate potential 
differences and associations between selected health characteristics, treatment regimens, 
and treatment outcomes.  This design was necessary to address the gap in the literature 
related to aflibercept.  Specifically, this study was designed to determine how aflibercept 
treatment for NAMD compared in populations with characteristics different from or 
treated in a manner that differed from the clinical trial populations.   
In Chapter 4, I will present data collection methods along with any discrepancies 
from the plan presented in Chapter 3.  I will also provide descriptive statistics pertaining 
to the three retinal practice populations.  Statistical analyses as proposed in Chapter 3 will 
be presented and explained relative to the research question posed. 
Data Collection 
I obtained the data for this study from EMR data from three retinal practices 
located in Hollywood, CA, Paducah, KY, and Cuyahoga Falls, OH from March 22, 2016 
through October 26, 2016.  Permission to use these data was granted by both the Walden 
University IRB and by each of the physicians in the retinal practices chosen.  As this was 
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a retrospective study wherein subject information was de-identified, it was not necessary 
to obtain informed consent to review the patients’ EMR information.  The original plan 
was to collect information on race/ethnicity, iris color, and NAMD genotype as a part of 
the selected health characteristics; however, these characteristics were not reported in the 
medical records of the selected retina specialists.  As well, the age variable was originally 
going to be calculated as the date of the database compared to the birthdate.  This 
calculation was determined to be faulty in that it could result in ages beyond which the 
subject had lived.  Instead, the age was calculated comparing the birthdate to the first day 
of aflibercept treatment.  Other changes in data collection or data naming conventions are 
defined in Table 3 and included: (a) the eye involved field was deleted as it was deemed 
to be unnecessary in that only study eye (SE) data were analyzed; (b) only data for the 
selected SEs were collected resulting in the renaming of several fields that had originally 
been specific to either OD or OS; (c) field renaming resulted in the following: 
DiagDate_SE, DiagTrtTime, Aflib1_SE with all subsequent treatment dates coded 
sequentially from Aflib1_SE, LogMAR1_SE with all subsequent VAs coded sequentially 
from LogMAR1_SE, OCT1_SE with all subsequent OCTs coded sequentially from 
OCT1_SE ; (d) a field of OCTDate1_SE and subsequent additional OCT dates were 
added to the data capture since the OCT date was not always the same as the treatment 
date; (e) additional ocular comorbidities and all systemic comorbidities were collected as 
verbatim terms and were not coded into body system categories as it was not deemed 
necessary; and (f) the data captured with regard to timing of diagnosis were compared to 
the date of first aflibercept treatment rather than the date of the database, as researchers 
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have stated that the improvement seen is more significant if the neovascularization is 
caught in its early phase  (Lim et al., 2012).  The final database structure was as follows 
in Table 3. 
Table 3 
Actual Variables and Coding for General NAMD Population 
Variable Definition Nature of 
Variable 
Coding of Variable 
Patient_No De-identified Patient 
Identification Number 
Text Site 1 (CA) =  
1001 – 1999 
Site 2 (KY) =  
2001 – 2999  
Site 3 (OH) =  
3001 – 4999 
 
DB_Date Date of the final database Date DD MMM YYYY 
Gender Patient’s Gender Dichotomous 1 = Male 
2 = Female 
Birthdate Patient’s Date of Birth Date DD MMM YYYY 
Age Age in years at the time the first 
Aflibercept treatment was given  
Numeric __.__ years 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
SmkHx Does the patient report a history 
of smoking? 
Dichotomous 1 = No 
2 = Yes 
AlcAbuse Does the patient report a history 
of alcohol abuse? 
Dichotomous 1 = No 
2 = Yes 
Total_OMH The total number of ocular 
comorbidities  
Numeric Number derived 
from summation of 
Ocular 
Comorbidities and 
OcuSpec1 through 
OcuSpec5 
Ocular 
Comorbidities 
Does the patient have any of the 
following ocular comorbidities?  
CAT = Cataract 
CMV = Cytomegalovirus 
Retinitis 
DME = Diabetic Macular Edema 
GLAUC = Glaucoma  
KCON = Keratoconus 
Numeric 1 = No 
2 = Yes 
3 = Unknown 
 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
 PVD = Posterior Vitreous 
Detachment RVO = Retinal Vein 
Occlusion 
UV = Uveitis 
OTHER = Other (Specify) 
  
OcuSpec1 
through 
OcuSpec5 
Specification of other Ocular 
Comorbidities 
Text Free text 
description of other 
ocular 
comorbidities not 
specified in the 
supplied list. 
Total_SMH The total number of systemic 
comorbidities  
Numeric Number derived 
from summation of 
SysComor1 
through 
SysComor20 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
SysComor1 
through 
SysComor20 
Specification of Systemic 
Comorbidities 
Text Free text 
description of other 
systemic 
comorbidities. 
Study Eye The study eye is identified as that 
eye which received treatment 
with Aflibercept first 
Categorical 1 = OD 
2 = OS 
DiagDate_SE Date the patient’s 
ophthalmologist diagnosed 
NAMD for the study eye 
Date DD MON YYYY 
DiagTrtTime Number of days from diagnosis 
of NAMD to treatment with 
aflibercept as calculated from the 
date of diagnosis to the date of 
the first treatment with 
Aflibercept 
Numeric __.__ days 
 
AflibTrt1_SE 
through 
AflibTrt13_SE 
Aflibercept treatment dates for 
the study eye  
Date DD MON YYYY 
(table continues)  
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Variable Definition Nature of 
Variable 
Coding of Variable 
LogMAR1_SE 
through 
LogMAR13_SE 
BCVA reported as ETDRS 
logMAR values for each 
treatment date 
Numeric _.__ 
 
OCTDate1_SE  
through 
OCTDate13_SE 
OCT evaluation dates for the 
study eye  
Date DD MON YYYY 
OCT1_SE 
through 
OCT13_SE 
OCT central retinal thickness 
associated with each injection of 
aflibercept 
Number ___._ µm 
 
For this study, I collected data from physicians’ EMR databases from March 22, 
2016 through October 26, 2016.  It was necessary to travel to the physician’s office in 
Hollywood, CA, to collect the required data for the project.  Data from the Paducah, KY 
and the Cuyahoga Falls, OH sites were made available online by the system administrator 
for the practice.  The patients identified as being appropriate for inclusion in this study 
comprised 199 total patients from the three retinal practices.  These 199 patients were 
culled from a total of 1,501 potential patients which was a 13.3% catchment.  My 
selection of the patients was based on the following criteria: 
• Diagnosis of NAMD in at least one eye. 
• Treatment with aflibercept intravitreal injections after approval in 2011. 
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• At least one BCVA and OCT assessment within approximately 1-month 
period prior to treatment with aflibercept. 
• At least three BCVA and OCT assessments during the approximately 1-year 
period following treatment with aflibercept. 
The first of these criteria was changed from the original plan to increase the potential 
subject pool.  The original criterion included a date restriction of between 2011 and 2014.  
The date restriction was determined unnecessary since the criterion associated with use of 
aflibercept resulted in a more effective culling of patients.  Originally, it was proposed to 
have collected 252 cases from the three retinal practices to achieve a 95% power to detect 
a Type 1 error at a = 0.05.  Based on the data available in the EMRs for these practices, 
199 Patients were identified from the three retinal practices.  Nonetheless, power to 
detect a Type 1 error at an a = 0.05 was maintained at 90% with the 199 patients 
included in the project. 
There were 179 patients identified from the initial sampling of EMR data at the 
retinal practice in Hollywood, CA.  From the initial sampling at this practice, the final 
number of patients included in the project database was 44.  This represents 24.6% of the 
total patients from the CA site and 22.1% of the total population.  There were 178 
patients from the initial sampling of EMR data at the retinal practice in Paducah, KY.  
From the initial sampling at this practice, the final number of patients included was 101.  
This represents 56.7% of the total patients from the KY site and 50.8% of the total 
population.  There were 1,144 patients from the initial sampling of EMR data at the 
retinal practice in Cuyahoga Falls, OH.  From the initial sampling at this practice, the 
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final number of patients included in the project database was 54.  This represents 4.7% of 
the total patients from the OH site and 27.1% of the total population. 
Results 
General Population Demographics 
Overall demographic descriptive statistics were performed on the final data 
sample collected.  The data from all three retinal practices combined included 78 males 
(39.2%) and 121 females (60.8%).  This represents a population that is slightly skewed (-
0.446) toward women.  This type of skewness is appropriate based on findings that 
NAMD is more prevalent in women (NEI, 2014).  The mean age of the population at the 
time of the subject’s first treatment with aflibercept was 78.8 ± 8.542 years.  This is 
skewed towards older age (-0.410), which is to be expected due to the age-related nature 
of NAMD (NEI, 2014).  The minimum age reported was 45 years and the maximum age 
was 95 years.  As has been mentioned previously, AMD is the most common cause of 
visual impairment after the age of 55 with the risk reaching 11.73% by the time 
individuals approach their eighth decade (Coleman et al., 2008; NEI, 2014).   
The smoking history and alcohol abuse findings were somewhat unexpected as 
having a history of smoking or alcohol abuse have been reported as being associated with 
incidence of NAMD (The Foundation of the American Academy of Ophthalmology, 
2015).  In the population studied, 137 (68.8%) patients reported no smoking history, 47 
(23.6%) patients reported having a history of smoking, and 15 (7.5%) patients did not 
report their smoking history; therefore, they were classified as unknown.  The findings 
for alcohol abuse were much less robust than had been anticipated with 174 (87%) 
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patients reporting no history of alcohol abuse, two (1%) patients reporting a history of 
alcohol abuse, and 24 (12%) patients not reporting their alcohol abuse history.  The 
patients with no report of alcohol abuse were also coded as unknown.  Since the patient 
reports of smoking and alcohol abuse history did not seem reliable, no further evaluations 
were performed on these variables. 
Patients in the population under study had an average of 3.00 ± 1.12 ocular 
comorbidities.  The minimum number of ocular comorbidities was one, and the 
maximum number was seven.  All patients were reported to have a diagnosis of AMD 
(ICD-9 code of 362.52).  The most common comorbidity reported other than AMD was 
cataract with 174 (87.4%) patients being diagnosed with cataract in at least one eye.  
Other ocular comorbidities reported were glaucoma (n = 29, 14.6%), posterior vitreous 
detachment (n = 20, 10.1%), retinal vein occlusion (n = 8, 4.0%), and uveitis (n = 1, 
0.5%).  Other ocular comorbidities that were not specified in the original listing were 
reported by 111 patients (55.8%).  The patients in this population reported having 5.65 ± 
3.15 systemic comorbidities. The minimum number of systemic comorbidities reported 
was zero and the maximum number was 20.  The most common systemic comorbidities 
(incidence > 15%) are listed in Table 4. 
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Table 4 
Systemic Comorbidities Reported at >15% Incidence 
Comorbidity Frequency and Percentage of Systemic Comorbidities  
(N = 199) 
Hypertension 132 66% 
Arthritis 87 44% 
Cancer 58 29% 
Hyperlipidemia 50 25% 
Hypothyroidism 38 19% 
Depression 35 18% 
Diabetes 34 17% 
Cardiovascular Disease 32 16% 
Note. N = Total number of patients. 
 
Regarding variables specific to NAMD for the overall study population, time 
from diagnosis to first aflibercept treatment, baseline BCVA, and baseline OCT were 
evaluated.  The mean between diagnosis with NAMD and the first treatment with 
aflibercept was 323.6 ± 410.6 days.  The large degree of variation in this variable was 
notable and was most likely due to NAMD diagnoses that were well before aflibercept 
was approved and marketed in 2011.  Mean baseline VA for the general population 
reported in ETDRS logMAR was 0.53 ± 0.39 and mean baseline OCT was 333.26 ± 
110.79 µm.  The mean number of aflibercept treatments given during the approximately 
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1-year period following the first aflibercept treatment was 7.24 ± 1.861 and the mean 
number of days between treatments was 63.4858 ± 33.02454.  Mean change from 
baseline BCVA was -0.0073 ± 0.30373 and mean change from baseline OCT was -
43.8750 ± 96.27885. 
Statistical Analyses 
Research Question 1.  
A one-way ANOVA was conducted to determine if age at the time of first 
treatment with aflibercept (AGE) was different between the three physician groups.  AGE 
had no significant outliers and was normally distributed across the population and 
between the physician groups, as assessed by visual inspection of a normal Q-Q Plot.  
There was homogeneity of variances as assessed by Levene’s test of homogeneity of 
variance (p = 0.468).  AGE data are presented as mean ± standard deviation in Table 5.   
Table 5 
AGE (years) Mean and Standard Deviation by Physician Group and Total 
Physician Group Number of Patients Mean Standard Deviation 
CA 44 79.98 9.444 
KY 101 77.88 8.222 
OH 54 79.50 8.332 
Total 199 78.78 8.542 
 
AGE was not statistically significantly different between the three physician practices, 
F(2,196) = 1.185, p = 0.308.  The null hypothesis was not rejected. 
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A c2 test of homogeneity was conducted to determine if GENDER was different 
between the three physician groups.  Gender data are presented as frequencies in Table 6.   
Table 6 
GENDER Frequencies by Physician Group and Total 
Physician Group Number of Patients Male Female 
CA 44 19 (43.2%) 25 (56.8%) 
KY 101 42 (41.6%) 59 (58.4%) 
OH 54 17 (31.5%) 37 (68.5%) 
Total 199 78 (39.2%) 121 (60.8%) 
GENDER was not statistically significantly different between the three physician groups, 
c2 = 1.1883, p = 0.390.  The null hypothesis was not rejected. 
A one-way ANOVA was conducted to determine if the average number of ocular 
comorbidities (OCULAR) per patient was different between the three physician groups. 
OCULAR had no significant outliers and was normally distributed across the population 
and between the physician groups, as assessed by visual inspection of a normal Q-Q Plot.  
There was homogeneity of variances as assessed by Levene’s test of homogeneity of 
variance (p = 0.470).  OCULAR data are presented as mean ± standard deviation in Table 
7.   
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Table 7 
OCULAR Mean and Standard Deviation by Physician Group and Total 
Physician Group Number of Patients Mean Standard Deviation 
CA 44 3.23 1.236 
KY 101 2.83 1.059 
OH 54 3.13 1.082 
Total 199 3.00 1.115 
OCULAR was not statistically significantly different between the three physician 
practices, F(2,196) = 2.467, p = 0.087.  The null hypothesis was not rejected. 
A one-way Welch ANOVA was conducted to determine if the average number of 
systemic comorbidities (SYSTEMIC) per patient was different between the three 
physician groups.  SYSTEMIC had no significant outliers and was normally distributed 
across the population and between the physician groups, as assessed by visual inspection 
of a normal Q-Q Plot.  There was heterogeneity of variances as assessed by Levene’s test 
of homogeneity of variance (p = 0.042).  SYSTEMIC data are presented as mean ± 
standard deviation in Table 8.   
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Table 8 
SYSTEMIC Mean and Standard Deviation by Physician Group and Total 
Physician Group Number of Patients Mean Standard Deviation 
CA 44 3.23 1.236 
KY 101 2.83 1.059 
OH 54 3.13 1.082 
Total 199 5.65 3.160 
SYSTEMIC was statistically significantly different between different physician groups, 
Welch’s F(2,196) = 4.106, p = 0.018. Games-Howell testing in the variable, SYSTEMIC, 
revealed a statistically significant difference between KY and OH with a mean difference 
in the number of systemic medical history items reported of 1.479 (95% CI [0.40,2.56, p 
= 0.004]).  The null hypothesis was rejected for SYSTEMIC between KY and OH.  For 
all other relationships, the null hypothesis was not rejected. 
A one-way Welch ANOVA was conducted to determine if the numbers of days 
between the diagnosis of NAMD and the first treatment with aflibercept (DIAGTRT) was 
different between the three physician groups. DIAGTRT had no significant outliers and 
was normally distributed across the population and between the physician groups, as 
assessed by visual inspection of a normal Q-Q Plot.  There was heterogeneity of 
variances as assessed by Levene’s test of homogeneity of variance (p < 0.001).  
DIAGTRT data are presented as mean ± standard deviation in Table 9.   
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Table 9 
DIAGTRT (days) Mean and Standard Deviation by Physician Group and Total 
Physician Group Number of Patients Mean Standard Deviation 
CA 44 484.25 594.997 
KY 101 338.01 337.864 
OH 54 164.96 282.467 
Total 199 323.39 410.607 
DIAGTRT was statistically significantly different between different physician 
groups, Welch’s F(2,196) = 7.986, p < 0.001.  Games-Howell testing in the variable, 
DIAGTRT, revealed a statistically significant difference in DIAGTRT between CA and 
OH with mean difference reported as 319.287 (95% CI [84.62,553.95, p = 0.005]), and 
the mean difference between KY and OH reported as 173.047 (95% CI [51.93,294.16, p 
= 0.003]).  The null hypothesis was rejected for DIAGTRT between CA and OH as well 
as between KY and OH.  For all other relationships, the null hypothesis was not rejected. 
A one-way ANOVA was conducted to determine if the Baseline VA (BLVA) was 
different between the different physician groups.  BLVA had no significant outliers and 
was normally distributed across the population and between the physician groups, as 
assessed by visual inspection of a normal Q-Q Plot.  There was homogeneity of variances 
as assessed by Levene’s test of homogeneity of variance (p = 0.106).  BLVA data are 
presented as mean ± standard deviation in Table 10.   
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Table 10 
BLVA (logMAR) Mean and Standard Deviation by Physician Group and Total 
Physician Group Number of Patients Mean Standard Deviation 
CA 44 0.4377 0.32155 
KY 101 0.6051 0.43855 
OH 54 0.4807 0.33678 
Total 199 0.5344 0.39416 
BLVA was statistically significantly different between the three physician practices, 
F(2,196) = 3.539, p = 0.031.  Tukey Post Hoc analysis revealed the mean increase in 
BLVA from KY to CA (0.16742, 95% CI [0.0014, 0.3335, p = 0.048]) was statistically 
significant.  The null hypothesis was rejected for BLVA between KY and CA.  For all 
other relationships, the null hypothesis was not rejected. 
A one-way ANOVA was conducted to determine if the Baseline OCT (BLOCT) 
was different between the different physician groups.  BLOCT had no significant outliers 
and was normally distributed across the population and between the physician groups, as 
assessed by visual inspection of a normal Q-Q Plot.  There was homogeneity of variances 
as assessed by Levene’s test of homogeneity of variance (p = 0.224).  BLOCT data are 
presented as mean ± standard deviation in Table 11.   
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Table 11 
BLOCT (µM) Mean and Standard Deviation by Physician Group and Total 
Physician Group Number of Patients Mean Standard Deviation 
CA 44 294.23 104.688 
KY 101 364.90 114.007 
OH 54 305.89 92.238 
Total 199 333.26 110.795 
BLOCT was statistically significantly different between the three physician practices, 
F(2,196) = 9.201, p < 0.001.  Tukey Post Hoc analysis revealed the mean increase in 
BLOCT from KY to CA (70.674, 95% CI [25.25, 116.09, p = 0.001]) was statistically 
significant.  The null hypothesis was rejected for BLOCT between KY and CA.  For all 
other relationships, the null hypothesis was not rejected. 
Research Question 2. 
A one-way ANOVA was conducted to determine if the average total number of 
aflibercept treatments given in the approximately 1-year period after the first aflibercept 
(NUMTRT) was different between the different physician groups.  NUMTRT had no 
significant outliers and was normally distributed across the population and between the 
physician groups, as assessed by visual inspection of a normal Q-Q Plot.  There was 
homogeneity of variances as assessed by Levene’s test of homogeneity of variance (p = 
0.355).  NUMTRT data are presented as mean ± standard deviation in Table 12.   
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Table 12 
NUMTRT Mean and Standard Deviation by Physician Group and Total 
Physician Group Number of Patients Mean Standard Deviation 
CA 44 8.55 1.956 
KY 101 7.08 1.647 
OH 54 6.46 1.634 
Total 199 7.24 1.861 
NUMTRT was statistically significantly different between the three physician practices, 
F(2,196) = 18.759, p < 0.001.  Tukey Post Hoc analysis revealed the mean increase in 
NUMTRT from CA to KY (1.466, 95% CI [0.74, 2.20]) was statistically significant (p < 
0.001), and the mean increase in NUMTRT from CA to OH (2.082, 95% CI [1.26, 2.90]) 
was statistically significant (p < 0.001).  The null hypothesis was rejected for NUMTRT 
between CA and KY as well as for CA and OH.  For all other relationships, the null 
hypothesis was not rejected. 
A one-way ANOVA was conducted to determine if the average number of days 
between aflibercept treatments (NUMDAY) was different between the different 
physician groups.  NUMDAY had no significant outliers and was normally distributed 
across the population and between the physician groups, as assessed by visual inspection 
of a normal Q-Q Plot.  There was homogeneity of variances as assessed by Levene’s test 
of homogeneity of variance (p = 0.196).  NUMTRT data are presented as mean ± 
standard deviation in Table 13.   
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Table 13 
NUMDAY (days) Mean and Standard Deviation by Physician Group and Total  
Physician Group Number of Patients Mean Standard Deviation 
CA 44 45.9056 16.79308 
KY 101 55.8789 20.76874 
OH 54 58.1092 21.49334 
Total 199 54.2790 20.58245 
NUMDAY was statistically significantly different between the three physician practices, 
F(2,196) = 5.081, p = 0.007.  Tukey Post Hoc analysis revealed the mean increase in 
NUMDAY from KY to CA (0.97327, 95% CI [1.3686,18.5780,] p = 0.018) and the mean 
increase in NUMDAY from OH to CA (12.20354, 95% CI [2.5290, 21.8780], p = 0.009).  
The null hypothesis was rejected for NUMDAY between KY to CA as well as between 
OH and CA.  For all other relationships, the null hypothesis was not rejected. 
Research Question 3. 
A one-way ANOVA was conducted to determine if change from baseline VA 
reported in the approximately one-year period following the first aflibercept treatment 
(BCVA) was different between the different physician groups.  BCVA had no significant 
outliers and was normally distributed across the population and between the physician 
groups, as assessed by visual inspection of a normal Q-Q Plot.  There was homogeneity 
of variances as assessed by Levene’s test of homogeneity of variance (p = 0.731).  BCVA 
data are presented as mean ± standard deviation in Table 14.   
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Table 14 
BCVA (logMAR) Mean and Standard Deviation by Physician Group and Total 
Physician Group Number of Patients Mean Standard Deviation 
CA 44 -0.0804 0.32370 
KY 101 0.0113 0.30985 
OH 54 0.0174 0.26973 
Total 199 -0.0073 0.30373 
BCVA was not statistically significantly different between the three physician practices, 
F(2,196) = 1.654, p < 0.194.  The null hypothesis was not rejected. 
A one-way Welch ANOVA was conducted to determine change from baseline 
OCT reported in the approximately one-year period following the first aflibercept 
treatment (OCT) was different between the three physician groups. OCT had no 
significant outliers and was normally distributed across the population and between the 
physician groups, as assessed by visual inspection of a normal Q-Q Plot.  There was 
heterogeneity of variances as assessed by Levene’s test of homogeneity of variance (p = 
0.042). OCT data are presented as mean ± standard deviation in Table 15.   
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Table 15 
OCT (µM) Mean and Standard Deviation by Physician Group and Total 
Physician Group Number of Patients Mean Standard Deviation 
CA 44 -36.5779 93.35451 
KY 101 -57.4915 110.93797 
OH 54 -24.3527 59.59982 
Total 199 -43.8750 96.27885 
OCT was not statistically significantly different between different physician groups, 
Welch’s F(2,196) = 2.276, p = 0.105. The null hypothesis was not rejected. 
Research Question 4. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between AGE and NUMDAY.  There was a monotonic relationship between AGE and 
NUMDAY, as assessed by visual inspection of a scatterplot.  There was no statistically 
significant correlation between AGE and NUMDAY, rs(199) = -0.066, p = 0.356.  The 
null hypothesis for association between AGE and NUMDAY was not rejected.  Further, a 
Spearman’s rank-order correlation was conducted to assess the relationship between AGE 
and NUMTRT.  There was a monotonic relationship between AGE and NUMTRT, as 
assessed by visual inspection of a scatterplot.  There was a statistically significant 
positive correlation between AGE and NUMTRT, rs(199) = 0.151, p = 0.033; therefore, 
the null hypothesis for association between AGE and NUMTRT was rejected.  
A point-biserial correlation was conducted between GENDER and NUMDAY.  
Assumption analyses of GENDER and NUMDAY showed (a) there were outliers, as 
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assessed by boxplot; (b) score was not normally distributed, as assessed by Shapiro-
Wilk's test (p < 0.05); but (c) there was homogeneity of variances, as assessed by 
Levene's test for equality of variances.  Although the assumptions were not all met, it was 
determined that the point-biserial correlation would be performed to gain some insight 
into whether an association might exist between GENDER and NUMDAY.  There was 
no statistically significant correlation between GENDER and NUMDAY, rpb(199) = -
0.021, p = 0.773   The null hypothesis for association between GENDER and NUMDAY 
was not rejected.  As well, a point-biserial correlation was conducted between GENDER 
and NUMTRT.  Assumption analyses of GENDER and NUMTRT showed (a) there were 
outliers, as assessed by boxplot; (b) score was not normally distributed, as assessed by 
Shapiro-Wilk's test (p < 0.05); but (c) there was homogeneity of variances, as assessed by 
Levene's test for equality of variances.  Although the assumptions were not all met, it was 
determined that the point-biserial correlation would be performed to gain some insight 
into whether an association might exist between GENDER and NUMTRT.  There was no 
statistically significant correlation between GENDER and NUMTRT, rpb(199) = 0.036, p 
= 0.618. The null hypothesis for association between GENDER and NUMTRT was not 
rejected. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between OCULAR and NUMDAY.  There was a monotonic relationship between the 
OCULAR and NUMDAY, as assessed by visual inspection of a scatterplot.  There was 
no statistically significant correlation between OCULAR and NUMDAY, rs(199) = 
0.027, p = 0.705; therefore, the null hypothesis for association between OCULAR and 
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NUMDAY was not rejected.  Further, a Spearman’s rank-order correlation was 
conducted to assess the relationship between OCULAR and NUMTRT.  There was a 
monotonic relationship between OCULAR and NUMTRT, as assessed by visual 
inspection of a scatterplot.  There was no statistically significant correlation between 
OCULAR and NUMTRT, rs(199) = -0.007, p = 0.922; therefore, the null hypothesis for 
association between OCULAR and NUMTRT was not rejected.  
A Spearman’s rank-order correlation was conducted to assess the relationship 
between SYSTEMIC and NUMDAY. There was a monotonic relationship between 
SYSTEMIC and NUMDAY, as assessed by visual inspection of a scatterplot.  There was 
a no statistically significant correlation between SYSTEMIC and NUMDAY, rs(199) = -
0.046, p = 0.520; therefore, the null hypothesis for SYSTEMIC and NUMDAY was not 
rejected.  Further, a Spearman’s rank-order correlation was conducted to assess the 
relationship between SYSTEMIC and NUMTRT.  There was a monotonic relationship 
between SYSTEMIC and NUMTRT, as assessed by visual inspection of a scatterplot.  
There was no statistically significant correlation between SYSTEMIC and NUMTRT, 
rs(199) = -0.107, p = 0.134; therefore, the null hypothesis for association between 
SYSTEMIC and NUMTRT was not rejected.  
A Spearman’s rank-order correlation was conducted to assess the relationship 
between DIAGTRT and NUMDAY.  There was a monotonic relationship between 
DIAGTRT and NUMDAY, as assessed by visual inspection of a scatterplot.  There was a 
statistically significant negative correlation between DIAGTRT and NUMDAY, rs(199) 
= -0.220, p = 0.002; therefore, the null hypothesis for DIAGTRT and NUMDAY was 
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rejected.  Further, a Spearman’s rank-order correlation was conducted to assess the 
relationship between DIAGTRT and NUMTRT.  There was a monotonic relationship 
between DIAGTRT and NUMTRT, as assessed by visual inspection of a scatterplot.  
There was statistically significant positive correlation between DIAGTRT and 
NUMTRT, rs(199) = 0.200, p = 0.005; therefore, the null hypothesis for association 
between DIAGTRT and NUMTRT was rejected. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between BLVA and NUMDAY.  There was a monotonic relationship between BLVA 
and NUMDAY, as assessed by visual inspection of a scatterplot.  There was no 
statistically significant correlation between BLVA and NUMDAY, rs(199) = 0.008, p = 
0.911; therefore, the null hypothesis for BLVA and NUMDAY was not rejected.  Further, 
a Spearman’s rank-order correlation was conducted to assess the relationship between 
BLVA and NUMTRT.  There was a monotonic relationship between BLVA and 
NUMTRT, as assessed by visual inspection of a scatterplot.  There was no statistically 
significant correlation between BLVA and NUMTRT, rs(199) = -0.098, p = 0.169; 
therefore, the null hypothesis for association between BLVA and NUMTRT was not 
rejected. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between BLOCT and NUMDAY.  There was a monotonic relationship between BLOCT 
and NUMDAY, as assessed by visual inspection of a scatterplot.  There was a statistically 
significant negative correlation between BLOCT and NUMDAY, rs(199) = -0.141, p = 
0.047; therefore, the null hypothesis for BLOCT and NUMDAY was rejected.  Further, a 
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Spearman’s rank-order correlation was conducted to assess the relationship between 
BLOCT and NUMTRT.  There was a monotonic relationship between BLOCT and 
NUMTRT, as assessed by visual inspection of a scatterplot.  There was no statistically 
significant correlation between BLOCT and NUMTRT, rs(199) = 0.089, p = 0.210; 
therefore, the null hypothesis for association between BLOCT and NUMTRT was not 
rejected. 
Research Question 5. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between AGE and BCVA.  There was a monotonic between AGE and BCVA, as 
assessed by visual inspection of a scatterplot.  There was no statistically significant 
correlation between AGE and BCVA, rs(199) = -0.055, p = 0.438.  The null hypothesis 
for association between AGE and BCVA was not rejected.  Further, a Spearman’s rank-
order correlation was conducted to assess the relationship between AGE and OCT.  There 
was a monotonic relationship between AGE and OCT, as assessed by visual inspection of 
a scatterplot.  There was no statistically significant correlation between AGE and OCT, 
rs(199) = 0.000, p = 0.997; therefore, the null hypothesis for association between AGE 
and OCT was not rejected.  
A point-biserial correlation was conducted between GENDER and BCVA.  
Assumption analyses of GENDER and BCVA showed (a) there were outliers, as assessed 
by boxplot; (b) score was not normally distributed, as assessed by Shapiro-Wilk's test (p 
< 0.05); but (c) there was homogeneity of variances, as assessed by Levene's test for 
equality of variances.  Although the assumptions were not all met, it was determined that 
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the point-biserial correlation would be performed to gain some insight into whether an 
association might exist between GENDER and BCVA.  There was no statistically 
significant correlation between GENDER and BCVA, rpb(199) = -0.008, p = 0.912.  The 
null hypothesis for association between GENDER and BCVA was not rejected.  As well, 
a point-biserial correlation was conducted between GENDER and OCT.  Assumption 
analyses of GENDER and OCT showed (a) there were outliers, as assessed by boxplot; 
(b) score was not normally distributed, as assessed by Shapiro-Wilk's test (p < 0.05); but 
(c) there was homogeneity of variances, as assessed by Levene's test for equality of 
variances.  Although the assumptions were not all met, it was determined that the point-
biserial correlation would be performed to gain some insight into whether an association 
might exist between GENDER and OCT.  There was no statistically significant 
correlation between GENDER and OCT, rpb(199) = 0.059, p = 0.409. The null hypothesis 
for association between GENDER and OCT was not rejected. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between OCULAR and BCVA.  There was a monotonic relationship between OCULAR 
and BCVA, as assessed by visual inspection of a scatterplot.  There was no statistically 
significant correlation between OCULAR and BCVA, rs(199) = 0.011, p = 0.881; 
therefore, the null hypothesis for association between OCULAR and BCVA was not 
rejected.  Further, a Spearman’s rank-order correlation was conducted to assess the 
relationship between OCULAR and OCT.  There was a monotonic relationship between 
OCULAR and OCT, as assessed by visual inspection of a scatterplot.  There was no 
statistically significant correlation between OCULAR and OCT, rs(199) = 0.042, p = 
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0.557; therefore, the null hypothesis for association between OCULAR and OCT was not 
rejected. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between SYSTEMIC and BCVA.  There was a monotonic relationship between 
SYSTEMIC and BCVA, as assessed by visual inspection of a scatterplot.  There was no 
statistically significant correlation between SYSTEMIC and BCVA, rs(199) = -0.102, p = 
0.152; therefore, the null hypothesis for SYSTEMIC and BCVA was not rejected.  
Further, a Spearman’s rank-order correlation was conducted to assess the relationship 
between SYSTEMIC and OCT.  There was a monotonic relationship between 
SYSTEMIC and OCT, as assessed by visual inspection of a scatterplot.  There was no 
statistically significant correlation between SYSTEMIC and OCT, rs(199) = -0.051, p = 
0.477; therefore, the null hypothesis for association between SYSTEMIC and OCT was 
not rejected. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between DIAGTRT and BCVA.  There was a monotonic relationship between DIAGTRT 
and BCVA, as assessed by visual inspection of a scatterplot.  There was no statistically 
significant correlation between DIAGTRT and BCVA, rs(199) = 0.128, p = 0.071; 
therefore, the null hypothesis for DIAGTRT and BCVA was not rejected.  Further, a 
Spearman’s rank-order correlation was conducted to assess the relationship between 
DIAGTRT and OCT.  There was a monotonic relationship between DIAGTRT and OCT, 
as assessed by visual inspection of a scatterplot.  There was statistically significant 
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positive correlation between DIAGTRT and OCT, rs(199) = -0.044, p = 0.533; therefore, 
the null hypothesis for association between DIAGTRT and OCT was not rejected. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between BLVA and BCVA.  There was a monotonic relationship between BLVA and 
BCVA, as assessed by visual inspection of a scatterplot.  There was a highly statistically 
significant negative correlation between BLVA and BCVA, rs(199) = -0.308, p < 0.001; 
therefore, the null hypothesis for BLVA and BCVA was rejected.  Further, a Spearman’s 
rank-order correlation was conducted to assess the relationship between BLVA and OCT.  
There was a monotonic relationship between BLVA and OCT, as assessed by visual 
inspection of a scatterplot.  There was highly statistically significant negative correlation 
between BLVA and OCT, rs(199) = -0.193, p = 0.006; therefore, the null hypothesis for 
association between BLVA and OCT was rejected. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between BLOCT and BCVA.  There was a monotonic relationship between BLOCT and 
BCVA, as assessed by visual inspection of a scatterplot.  There was no statistically 
significant correlation between BLOCT and BCVA, rs(199) = -0.025, p = 0.726; 
therefore, the null hypothesis for BLOCT and BCVA was not rejected.  Further, a 
Spearman’s rank-order correlation was conducted to assess the relationship between 
BLOCT and OCT.  There was a monotonic relationship between BLOCT and OCT, as 
assessed by visual inspection of a scatterplot.  There was a highly statistically significant 
negative correlation between BLOCT and OCT, rs(199) = -0.721, p < 0.001; therefore, 
the null hypothesis for association between BLOCT and OCT was rejected. 
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Research Question 6. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between NUMDAY and BCVA.  There was a monotonic relationship between 
NUMDAY and BCVA, as assessed by visual inspection of a scatterplot.  There was no 
statistically significant correlation between NUMDAY and BCVA, rs(199) = 0.103, p = 
0.148; therefore, the null hypothesis for NUMDAY and BCVA was not rejected.  
Further, a Spearman’s rank-order correlation was conducted to assess the relationship 
between NUMDAY and OCT.  There was a monotonic relationship between NUMDAY 
and OCT, as assessed by visual inspection of a scatterplot.  There was a highly 
statistically significant negative correlation between NUMDAY and OCT, rs(199) = 
0.197, p = 0.005; therefore, the null hypothesis for association between NUMDAY and 
OCT was rejected. 
A Spearman’s rank-order correlation was conducted to assess the relationship 
between NUMTRT and BCVA.  There was a monotonic relationship between NUMTRT 
and BCVA, as assessed by visual inspection of a scatterplot.  There was no statistically 
significant correlation between NUMTRT and BCVA, rs(199) = -0.032, p = 0.656; 
therefore, the null hypothesis for NUMTRT and BCVA was not rejected.  Further, a 
Spearman’s rank-order correlation was conducted to assess the relationship between 
NUMTRT and OCT.  There was a monotonic relationship between NUMTRT and OCT, 
as assessed by visual inspection of a scatterplot.  There was a highly statistically 
significant negative correlation between NUMTRT and OCT, rs(199) = -0.191, p = 0.007; 
therefore, the null hypothesis for association between NUMTRT and OCT was rejected. 
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Summary  
In this study, I examined whether significant differences existed with regard to 
selected health characteristics, treatment regimens, and treatment outcomes for patients 
with NAMD treated with aflibercept from three private, retinal practices in 
geographically disperse population centers in the United States.  Potential associations 
between selected health characteristics, treatment regimens, and treatment outcomes were 
evaluated to address the gap in the literature related to aflibercept.  Finally, I evaluated 
how aflibercept treatment for NAMD performed in populations with characteristics 
different from or treated in a manner that differed from the clinical trial populations.   
There were differences between the three different retinal practices regarding the 
number of systemic medical history items reported for KY/OH.  Additionally, the time 
from the initial diagnosis with NAMD and the first treatment with aflibercept differed 
between CA/OH and KY/OH.  BLVA and BLOCT differences were noted between 
KY/CA.  The number of days between aflibercept treatments differed between OH/CA, 
and the total number of aflibercept treatments differed between CA/KY and CA/OH.  
Associations were noted in age and number of aflibercept treatments, time from diagnosis 
to first aflibercept treatment and number of days between aflibercept treatments, time 
from diagnosis to first aflibercept treatment and total number of aflibercept treatments, 
BLVA and BCVA, BLVA and OCT, and BLOCT and OCT. 
In Chapter 5, I will review the results provided in Chapter 4 and how they related 
to current literature and the appropriateness of extrapolating the results to the larger 
population of patients being treated with aflibercept.  In Chapter 5, I will also provide 
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insight into the limitations of the study and any recommendations for future research in 
this field.  Finally, conclusions pertaining to this study will be detailed.  
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Chapter 5: Discussions, Conclusions, and Recommendations 
Introduction 
This study was a retrospective, contrasted group, cross-sectional, secondary 
analysis of data.  The purpose of this study was to evaluate selected health characteristics, 
treatment regimens, and treatment outcomes for patients with NAMD treated with 
aflibercept from three private, retinal practices in geographically disperse population 
centers in the United States.  The aim of the study was to determine whether differences 
or associations existed in these populations.   
The key findings from this study were that NAMD patients included from the 
three geographically disperse retinal practices were similar with respect to the some of 
the more general selected health characteristics (i.e., age, gender, and ocular 
comorbidities).  There were significant differences between NAMD patients in these 
physician practices with regard to some of the more specific selected health 
characteristics (i.e., systemic comorbidities, time from initial diagnosis to first treatment 
with aflibercept), treatment regimens, and treatment outcomes.  The correlation analyses 
that I performed were run with the NAMD patient data from all three geographically 
disperse retinal practices.  In the NAMD populations evaluated from the three retinal 
practices, there was little correlation between the selected health characteristics as 
compared to treatment regimens or to treatment outcomes; however, there were 
significant associations noted between treatment regimens and treatment outcomes.  I will 
use the remainder of Chapter 5 to elaborate the specifics of these findings and provide 
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insight into how this research applies not only to prior reviewed literature but also to 
what impact this study research could have on future research.   
This study was limited by the inaccessibility to the variables of race/ethnicity, iris 
color, and genotype in the EMR of the three retinal practices.  As such, these three 
variables were not a part of the final comparisons.  If these variables had been available, 
there would have been the opportunity for additional understanding of the health 
characteristics of the NAMD population used in this study.  Additionally, this study was 
somewhat limited by the number of patients originally planned to be captured versus the 
amount of data available in the EMR.  Although it was the case that data from 199 
instead of 252 patients were included, the statistical findings were still robust as I will 
further discuss in this chapter.   
As for this study’s implications for positive social change, this type of study that 
can be performed on existing electronic data could lead to a better understanding of when 
and how medications are used.  Studies could be performed on a single practice basis or 
on larger populations (e.g., city, state, country).  Fostering use of EMR data for gaining 
an understanding of patient demographics and health characteristics could impact the use 
of treatment regimens and lead to better treatment outcomes. 
Interpretation of Findings 
Results Pertaining to Prior Literature 
Comparing the findings of this study to the prior literature reviewed for this study 
led to a better understanding of how these three geographically disperse retinal practice 
populations fit into the overall population of NAMD patients treated with aflibercept.  It 
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was unfortunate that the race/ethnicity and iris color data were not available in the EMRs 
for the retinal practices used, as this might have increased understanding of the 
associations between the variables evaluated.  Both the overall (60.8%) and the three 
specific NAMD populations (CA = 56.8%, KY = 58.4%, and OH = 68.5%) were made 
up of greater numbers of females.  This skewing towards a greater risk of developing 
NAMD for females is supported by the literature (Coleman et al., 2008; NEI, 2014).  
Additionally, the mean age in the general population (78.78 ± 8.542) and the three 
specific populations (CA = 79.98 ± 9.449, KY = 77.88 ± 8.222, OH = 79.50 ± 8.332) was 
similar to that reported in in prior literature (Lim et al., 2012; NEI, 2015b).  With regard 
to ocular comorbidities, this study supported the findings of prior literature (The 
Foundation of the American Academy of Ophthalmology, 2015) with the finding that the 
presence of cataract was noted in 174 (87.4%) of the NAMD patients in the study.   
The package insert for aflibercept that provides the instructions for administration 
of the product states that aflibercept should be given once per month for the first 3 
months and then every other month for the remaining 9 months of the year (FDA, 2011). 
This translates to a total of approximately 7.5 doses per year.  The findings of this study 
were quite close to that recommendation with 7.24 ± 1.861 doses given in the overall 
population of 199 patients.  Change from baseline BCVA and change from baseline OCT 
showed promising increase in visual function (-0.0073 ± 0.30373 logMAR) and decrease 
in central macular thickness (-43.8750 ± 96.27885), which are how efficacy of aflibercept 
treatment is evaluated in the NAMD patient populations (FDA, 2011).   
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 Generally, the findings of this study show that the population characteristics of 
NAMD patients in the three retinal practices were similar to an epidemiologically 
appropriate patient population, at least with respect to the variables that could be 
collected from the EMR at the practices used.  The number of injections patients receive 
in these practices is aligned with the aflibercept package insert.  The timing of the 
injections was also aligned with the information provided in the aflibercept package 
insert. 
Results Pertaining to Retinal Practices 
Research Questions 1–3 pertained to determining whether the three 
geographically disperse retinal practices used in this study were comparable to each 
other.  I evaluated a total of 1,501 NAMD EMRs for patients at the three retinal practices 
to capture information on selected health characteristics, treatment regimens, and 
treatment outcomes based on treatment with aflibercept.  Of this total, 199 patients were 
considered qualified for further review based on the criteria noted Chapter 3.  For Tables 
16 and 17, a plus sign (+) denotes that the mean differences between the retinal practice 
combinations noted in the table for a health characteristic showed not statistically 
significant differences.  A minus sign (-) denotes that statistically significant mean 
differences were noted in the health characteristic noted in the table between the retinal 
practice combination noted.  The testing performed for the selected health characteristic 
comparisons between retinal practices was either a one-way ANOVA or a one-way 
Welch ANOVA.  My determination of the use of the Welch one-way ANOVA was based 
on whether the variances were different between the retinal practices being compared on 
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the health characteristics. Table 16 reports comparisons for the selected health 
characteristics between the three retinal practices.  
Table 16 
Comparison of Selected Health Characteristics by Physician Group 
Physician 
 Group 
Combina-
tions 
Age Gender Ocular 
Comor-
bidities 
Systemic 
Comor-
bidities 
Days from 
NAMD Diagnosis 
to First 
Aflibercept 
Treatment 
BL 
VA 
BL 
OCT 
CA/KY + + + + + - - 
KY/OH + + + - - + + 
CA/OH + + + + - + + 
Note. “+” denotes no statistically significant difference in the mean differences for site pairing. 
“-“ denotes statistically significant difference in the mean differences for site pairing. 
The practices were alike in the main demographic and health characteristics of 
AGE, GENDER, and OCULAR.  No statistically significant differences were noted in 
these three general health characteristics, and AGE, GENDER, and OCULAR were 
aligned with what has been noted epidemiologically for the NAMD patient population 
(NEI, 2014, 2015b).  Consequently, I determined that the retinal practices were 
representative of the general NAMD population in the health characteristics that were 
significant to have been reported by an ophthalmologist (e.g., age, gender, and ocular and 
systemic comorbidities).  
118 
 
There were more inconsistencies between KY and the other two retinal practices 
(i.e., CA and OH) regarding selected health characteristics.  In this evaluation, baseline 
BCVA and baseline OCT findings were especially notable in the mean difference 
between CA and KY.  Considering that the mean baseline BCVA for the general 
population was 0.53 ± 0.39 logMAR, a mean difference between CA and KY of 0.17 
logMAR indicates that KY’s patients were significantly more visually impaired at the 
beginning of their aflibercept treatment cycles.  The same issue holds true for baseline 
OCT.  Mean baseline OCT for the general population was 333.26 ± 110.795 µm.  The 
mean difference reported between CA and KY (70.674 µm), again, means that KY’s 
patients started at a much more advanced level or central retinal thickness at the initiation 
of their aflibercept treatment cycles.  The comparison between KY and OH further 
supports the notion that KY’s retinal practice may have been somewhat different with 
regard to the health characteristics than either CA or OH.   
While not as significant, KY did show a disparity on the number of systemic 
medical history items and the days from diagnosis to first treatment with aflibercept.  The 
differences between the three retinal practices that pertain to NAMD specifically may be 
due to the difference in sample size between the three practices.  KY accounted for 
slightly over 50% of the total patients in this research project.  A difference in 
methodology for capturing BCVA or OCT assessments or in recording information such 
as diagnosis date into the EMR may have caused this practice to exhibit notable 
differences.  Table 17 reports comparisons for treatment regimens and treatment 
outcomes.   
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Table 17 
Comparison of Treatment Regimens and Treatment Outcomes by Physician Group 
Physician 
 Group 
Combinations 
Number of 
Days between 
Treatments 
Number of 
Treatments 
Best 
Corrected 
Visual Acuity 
Optical 
Coherence 
Tomography 
CA/KY - - + + 
KY/OH + + + + 
CA/OH - - + + 
Note. “+” denotes no statistically significant difference in the mean differences for site pairing. 
“-“ denotes statistically significant difference in the mean differences for site pairing. 
Pertaining to treatment regimens, there were significantly notable differences within 
the CA practice as compared to the other two retinal practices.  CA provided more 
aflibercept treatments (8.55 ± 1.956) to each patient than either KY (7.08 ± 1.647) or OH 
(6.46 ± 1.634) with CA having significantly fewer days between aflibercept treatments 
(45.9056 ± 16.79308) than OH (58.1092 ± 21.49335) or KY (55.8789 ± 20.76874).  
These treatment regimen differences between the three retinal practices did not translate 
to significant differences in the treatment outcomes.  In general, it appears that the three 
retinal practices were quite similar to each other and to the general population of patients 
treated for NAMD with aflibercept.  Although I noted differences in some of the health 
characteristics and aflibercept treatment regimens, this did not translate to significant 
differences in the treatment outcomes. 
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Results Pertaining to Associations 
 Research Questions 4–6 pertained to whether there were associations between the 
selected health characteristics, treatment regimens, or treatment outcomes in the NAMD 
populations I analyzed from the three geographically disperse retinal practices in the 
United States.  In Table 18, findings for associations between health characteristics and 
treatment regimens are reported. 
Table 18 
Significant Spearman’s Correlations for Selected Health Characteristics, Treatment 
Regimens, and Treatment Outcomes 
Comparison Spearman Correlation Coefficient p-value 
AGE + NUMTRT rs (199) = 0.151 0.033 
DIAGTRT + NUMTRT rs (199) = - 0.200 0.005 
DIAGTRT + NUMDAY rs (199) = - 0.220 0.002 
BLVA + BCVA rs (199) = - 0.308 < 0.001 
BLVA + OCT rs (199) = - 0.193 0.006 
BLOCT + OCT rs (199) = - 0.721 < 0.001 
BLOCT + NUMDAY rs (199) = -0.141 0.047 
NUMDAY + OCT rs (199) = 0.197 0.005 
NUMTRT + OCT rs (199) = - 0.191 0.007 
The first of the comparisons in Table 18 indicated that a positive correlation 
existed between age at the time of first aflibercept treatment and number of aflibercept 
treatments given meaning that as the age at first treatment with aflibercept increased as 
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did the number of treatments given.  Although this is a statistically significant correlation, 
it is not intuitively reasonable.  This would seem to mean that the older the patient was 
when they were first started aflibercept treatment, the more likely they were to receive 
more treatments.  This is an interesting correlation, if it were to hold true in future 
research, as it may indicate that physicians treat more aggressively with older patients. 
There was a negative correlation between both the time from NAMD diagnosis to 
first aflibercept treatment as compared to the number of aflibercept treatments given and 
the number of days between aflibercept treatments.  This indicated that the longer the 
time period was between when the subject was diagnosed with NAMD and when they 
first received aflibercept treatment, the more likely they were to receive fewer treatments 
with aflibercept in a shorter period of time.  While neither of these correlations was 
strongly negative (-0.200 and -0.220, respectively), the correlation is highly statistically 
significant (p = 0.005 and p = 0.002, respectively).  This finding indicated that the three 
retinal specialists used for this study were seemingly not as aggressive in their treatment 
of NAMD patients with more advanced disease.  
There was also a negative correlation between baseline BCVA and change from 
baseline BCVA, baseline BCVA and change from baseline in OCT, and baseline OCT 
and change from baseline OCT.  As baseline BCVA increased, change from baseline 
BCVA and change from baseline OCT both decreased.  As baseline OCT increased, 
change from baseline OCT decreased.  Decreases in both change from BCVA and in 
change from baseline OCT were considered an improvement.  The meaning of this was 
that with worse initial VA, there was a greater possibility for improvement in both BCVA 
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and in OCT findings. As well, increased initial central retinal thickness as seen on OCT 
was more likely to improve.  The correlations between baseline BCVA and change from 
baseline BCVA and change from baseline OCT were not strongly negative (-0.308 and -
0.193, respectively) but were highly statistically significant (p < 0.001 and p = 0.006, 
respectively).  The correlation between baseline OCT and change from baseline OCT was 
strongly negative (-0.721) and highly statistically significant (p < 0.001).  This indicated 
that although a patient may start from a significantly negative assessment in terms of 
BLVA and BLOCT findings, there was a correlation with this negative initial assessment 
and a greater improvement with aflibercept treatment in these three retinal practices.  
Finally, there was a positive correlation between the number of days between 
treatments and both baseline OCT and change from baseline in OCT.  As the number of 
days between treatments increased the baseline OCT was seen to be increased (worse) 
and the change from baseline OCT increased (worse).  There was a negative correlation 
between and the number of treatments given and change from baseline in OCT.  As the 
number of treatments increased, the change from baseline OCT decreased (better).   
When evaluating these results in terms of the burden of treatment theoretical 
framework, it is clear that the burden of aflibercept treatment is onerous both on a 
financial and a personal basis.  Having to receive over seven intravitreal injections over 
the course of a year takes not only a great deal of time but also financial and personal 
resources as well.  However, it can be posited that by receiving these injections, the 
appropriate patient population can benefit from the treatment.  More treatments may 
mean greater time and money, but it may also mean a greater chance to regain some 
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visual function.  Gaining visual function could lessen the burden of blindness due NAMD 
to the benefit of the patient, the healthcare system, and the community. 
Limitations of the Study 
One of the main limitations of the study with respect to what was originally 
planned was that race/ethnicity, iris color, and NAMD genotype were not available in the 
EMRs of the retinal practices.  This limited the study to examination of age and gender as 
the main demographic characteristics that were evaluated. Although this was a significant 
limitation, the remainder of the data collected was quite robust and provided an ample 
view of how aflibercept treatments are performed and what the outcomes of the 
treatments were.  A secondary limitation was that the number of cases that could be 
culled from the EMR data at the three retinal practices was somewhat lower than 
anticipated and was not evenly dispersed between the three practices.  Nonetheless, the 
power to detect a Type 1 error at an a = 0.05 was maintained at 90% with the 199 
patients included in the project. 
Recommendations  
Since this study supported prior literature and clinical research findings pertaining 
to the population, health characteristics, treatment regimens, and treatment outcomes, it is 
imperative for this information to be shared and expanded upon in different therapeutic 
areas.  Use of EMR has been shown to be an effective means of gathering and analyzing 
available data to evaluate important medical conditions and treatments.  Expanding the 
use of EMR in the manner employed in this study is not difficult and not particularly time 
consuming.  EMR is an untapped resource that could and should be used in 
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postmarketing efforts, in clinical research, and public health programs.  Additional 
studies of interest would be to evaluate other retinal conditions (e.g., diabetic macular 
edema, retinal vein occlusion, retinitis pigmentosa) and other treatments to determine 
whether the outcomes from different diseases can be followed by using EMR.  Further, 
looking at the same type of NAMD population as pertains to other treatments would be 
elucidating and would not cost a great deal in terms of financial or personal investment.  
Finally, the information gleaned from this study could be used to develop public health 
initiatives that would target specific populations for early testing, watchful waiting, 
prophylactic care with vitamin supplements, and early treatment leading to better 
treatment outcomes. 
Implications 
The major implication of this study is that the clinical research performed in 
support of marketing aflibercept as an effective treatment for NAMD has been reinforced 
by general use of the product in NAMD patients in the three retinal geographically 
disperse practices used.  Results of this study will be provided to the three retinal 
practices, allowing the retinal specialist at the identified practices to gain more insight 
into their NAMD patient population.  It is apparent from analysis of the data, NAMD 
patients from these three retinal practices did benefit from aflibercept treatment when the 
approved dosing regimen was used.  As well, the correlation that was seen that increasing 
the number of aflibercept treatments and decreasing the number of days between 
aflibercept treatments could provide the clinical justification needed to provide additional 
treatments when clinically indicated.  With NAMD treatment being a significant portion 
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of the public financial burden in the form of Medicare payouts (Silver, 2014), this study 
may help alleviate some of the uncertainty associated with trying to determine the most 
appropriate regimen (i.e., number and timing of aflibercept treatments) for a patient.  
Although the financial burden is still onerous, it is justified when treatments are used on 
appropriate patient populations 
Regarding social change, research that can be performed on existing electronic 
data could lead to a better understanding of when and how treatments are used.  Fostering 
use of EMR data for gaining an understanding of patient demographics and health 
characteristics could impact treatment regimens and lead to better treatment outcomes.  
Evidence-based and data driven treatment of patients would seem to be an optimal 
method of practicing medicine, which drives improvements in the health of the 
population.  Having access to data collected in EMR, it would behoove a physician to use 
the information to the best of his or her ability and to the benefit of his or her patients.  
Changing to an electronic format of capturing health information should be a boon to the 
medical industry (i.e., both medical practice and public health) for the potential to be 
used effectively and efficiently to find, educate, and treat patients.  One final implication 
for the use of EMR to understand populations and treatments is to share appropriate 
information on a patient or summary basis with public health authorities.  Again, basing 
public health initiatives, programs, budgets, and outcomes on evidence found in EMR 
data could lead to better public understanding of disease and treatment. 
This study will be shared with each of the practices involved for the retina 
specialists to gain a better understanding of their own practice and what can be 
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accomplished by mining the data they already have.  It is intended that the methods used 
to capture and analyze the data for this project will be shared and appropriate personnel 
taught how best to find, organize, and analyze the available data.  The aim for such 
sharing of information is to teach others in medicine and public health how to use data 
already available. 
Conclusion 
Generally, the findings of this study showed that the population characteristics of 
NAMD patients evaluated from three retinal practices were similar to an 
epidemiologically appropriate patient population (NEI, 2014, 2015a), at least with respect 
to the selected health characteristic variables that could be collected from the EMR (e.g., 
age, gender, and ocular and systemic comorbidities).  Additionally, treatment regimens 
used by these three retinal practices were aligned with the information provided in the 
aflibercept package insert.  Based on the treatment outcomes of increase in visual 
function (BCVA) and decrease in central macular thickness (OCT), the indication is that 
aflibercept treatment was effective in the population culled from the three retinal 
practices.  Finally, the findings are supported by prior literature and indicate that the 
foundation laid by aflibercept clinical research performed in support of the approval to 
market aflibercept as an effective product for the NAMD patient population was used for 
the benefit of the NAMD patients in the three geographically disperse retinal practices. 
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